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RESUMEN EN CASTELLANO 
1 INTRODUCCIÓN 
1.1 Mielitis transversa aguda idiopática: Definición y criterios según la 
Transverse Myelitis Consortium Working Group 
La mielitis transversa aguda (MTA) no compresiva hace referencia a una 
inflamación de la médula espinal que deriva en manifestaciones neurológicas de 
comienzo agudo o subagudo en forma de pérdida de fuerza, alteración sensitiva o 
disfunción autonómica. Existen diversas causas que pueden ser el origen de una 
MTA. Las enfermedades desmielinizantes son la causa más frecuente de MTA, 
siendo la Esclerosis Múltiple (EM) su entidad más representativa. Otras 
entidades más infrecuentes como la Neuromielitis Óptica (NMO) o la 
Encefalomielitis Aguda Diseminada (ADEM) pueden comenzar en forma de 
mielitis longitudinalmente extensa (LETM), extendiéndose a lo largo de tres o 
más cuerpos vertebrales contiguos. Las enfermedades sistémicas autoinmunes 
como el Síndrome de Sjogren, el Lupus eritematoso sistémico, la Sarcoidosis, la 
Enfermedad de Behçet o el síndrome antifosfolípido son otro amplio grupo de 
enfermedades causante de MTA. Por último y con una incidencia menor, las MTA 
pueden ser secundarias a agentes infecciosos (entre ellos; herpes virus, 
Mycoplasma pneumoniae o Mybacterium tuberculosis), procesos vasculares 
(infartos espinales, fístulas durales o malformaciones arteriovenosas), 
embolismos fibrocartiloginosos, tumores intramedulares (ependinomas o 
astrocitomas) o síndromes paraneoplásicos (CRMP-5/CV-2, anfifisina, ANNA-2 o 
GAD) (Jacob A, et al. 2008; Kitley J, et al. 2012). A pesar de un exhaustivo estudio 
etiológico, la causa no se llegará a identificar hasta en el 15,6% de los pacientes 
con un primer evento de MTA (MTAI). En el año 2002, la Transverse Myelitis 
Consortium Working Group (TMCWG) propuso unos criterios diagnósticos 
(Tabla 1), con el objetivo de unificar y homogeneizar este grupo de pacientes 
(TMCWG 2002). 
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Tabla 1. Criterios diagnósticos de mielitis aguda transversa idiopática (MTAI)  
 
 
 
1.2 Pronóstico funcional de los pacientes con una mielitis transversa aguda 
Un tercio de los pacientes con un primer episodio de MTA no presentará secuelas 
o éstas serán ligeras, un tercio presentará un grado moderado de discapacidad y 
un tercio de los pacientes estarán confinados a una silla de ruedas según los 
estudios clásicos (Lipton HL, et al. 1973; Christensen PB, et al. 1990). La proporción de 
pacientes con un episodio de MTAI con mal pronóstico (incapacidad para la 
deambulación autónoma) se ha observado en el 35,8% de los pacientes en 
estudios que han evaluado mielitis bajo los criterios de la TMCWG (de Seze J, et al. 
2005). Entre los factores asociados a un mal pronóstico funcional en pacientes con 
MTA se han descrito el dolor lumbar, el rápido comienzo de los síntomas, la alta 
frecuencia de recidivas, una mayor discapacidad o afectación motora al 
comienzo de los síntomas, la presencia radiológica de LETM y alteraciones 
neurofisiológicas como denervación en extremidades inferiores o anormalidad en 
los potenciales evocados sensitivo- motores. En pacientes con un primer episodio 
de MTAI según los criterios de la TMCWG 2002, una mayor discapacidad al 
comienzo de los síntomas, el shock medular y la presencia de LETM son los 
únicos factores descritos asociados a un mal pronóstico (de Seze J, et al. 2005; Bruna 
J, et al. 2006; Li R, et al. 2011) Otros factores moleculares como la proteína 14-3-3 o 
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la cistatina C han sido relacionados con mal pronóstico funcional en pacientes 
con un primer episodio de MTA (Irani D, et al. 2000; Gajofatto A, et al. 2010). 
 
1.3 Esclerosis Múltiple y mielitis transversa aguda 
La EM es la enfermedad crónica del Sistema Nervioso Central (SNC) más 
frecuente e invalidante en pacientes jóvenes de países occidentales. Se 
caracteriza por una afectación desmielinizante multifocal del SNC. En el 85% de 
los pacientes que desarrollarán EM, el comienzo clínico consiste en una 
afectación neurológica aguda o subaguda denominada síndrome neurológico 
aislado o " clinically isolated syndrome" (CIS) (Confavreux C, et al. 2000). La mielitis 
representa aproximadamente el 21% de los CIS y la manera de presentación más 
frecuente es en forma de inflamación medular parcheada e incompleta 
denominada mielitis transversa parcial aguda. El riesgo de conversión a EM en 
pacientes con un primer episodio medular varía entre 44 y 92%. Si se evalúan 
únicamente los pacientes sin lesiones cerebrales, la frecuencia disminuye hasta el 
15-45% y, finalmente, hasta el 0-11% si se aplican los criterios de la TMCWG 
2002 para IATM (de Seze J, et al. 2005; Bruna J, et al. 2006; Li R, et al. 2010). Los factores 
de conversión a EM descritos tras un primer episodio medular son la historia 
familiar de EM, el comienzo temprano de los síntomas, el género femenino, una 
mayor discapacidad o afectación sensitiva al inicio de los síntomas, la presencia 
de un índice IgG anormal (>0.7) o tener pleocitosis en líquido cefaloraquídeo 
(LCR), así como la localización posterolateral de la lesión medular por 
Resonancia magnética (RM). Sin embargo, los dos factores que mejor predicen la 
conversión a EM son la presencia de bandas oligoclonales (BOC) en LCR y la 
carga lesional en la RM cerebral (Sellner J, et al. 2008; Bourre B, et al. 2012; Ruet A, et al. 
2011; Cordonnier C, et al. 2003). 
La búsqueda de marcadores de conversión a EM es motivo de múltiples estudios. 
Sin embargo, estos marcadores continúan sin ser completamente dilucidados en 
pacientes con MTAI, debido en gran parte a su reducida incidencia y a la baja 
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probabilidad de conversión a EM tras los rigurosos criterios propuestos por la 
TMCW 2002. 
 
1.4 Neuromielitis óptica y mielitis transversa aguda 
La NMO es una rara enfermedad desmielinizante del SNC cuyos síntomas 
cardinales son la mielitis en forma de LETM y la neuritis óptica (NO). Entre estos 
pacientes, la LETM se observa hasta en el 45,6% como un primer episodio y 
hasta el 17,6% de los pacientes pueden presentar un primer episodio en forma de 
LETM y ON de manera simutanea. En 2004, el grupo de la Clínica Mayo 
describió el anticuerpo anti-aquaporina 4 (AQP4-ab) dirigido contra el canal 
AQP4 situado en los pies astrocitarios (Lennon V, et al. 2004). Hasta el 75% de los 
pacientes diagnosticados de NMO presentan este anticuerpo (Marignier R, et al. 
2013). Desde su descripción, los pacientes con AQP4-ab y que presenten formas 
limitadas de NMO (episodios únicos o recurrentes de LETM y NO recurrentes o 
bilaterales simultáneas), formas óptico-espinales asiáticas de EM, NO o LETM 
asociadas a enfermedades sistémicas así como las NO o mielitis que presenten 
lesiones cerebrales típicas de NMO se engloban en el denominado espectro-NMO 
(NMOSD) (Wingerchuk D, et al. 2007). 
La frecuencia de los AQP4-ab entre los pacientes con un primer episodio de 
LETM se ha descrito hasta en un 89% de pacientes, aunque dichas frecuencias 
son variables en función de los estudios (Kitley J, et al. 2013; Sepúlveda M, et al. 2013). 
Se han descrito ciertas diferencias entre los pacientes con un primer episodio de 
LETM positivos y negativos para AQP4-ab. Las principales se citan a 
continuación. Existe una predisposición hacia el género masculino, una edad de 
presentación más joven y una menor frecuencia de recidivas en los pacientes 
AQP4-ab negativos. Sin embargo, los pacientes AQP4-ab positivos presentan de 
manera más frecuente síntomas de tronco encefálico y una mayor discapacidad al 
inicio de los síntomas (Kitley J, et al. 2013; Sepúlveda M. et al. 2013; Hyun JW, et al. 2015; 
Iorio R, et al. 2013). 
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Los AQP4-ab son un importante marcador de recurrencia en pacientes con 
LETM y por tanto, de conversión a NMOSD (Weinshenker BG, et al. 2006). Aunque el 
índice de conversión a NMO es mayor en pacientes con LETM y AQP4-ab (83%), 
hasta el 25% de los pacientes negativos para AQP4-ab también convertirán a 
NMO (Iorio R, et al. 2013; Chang KH, et al. 2013). 
 
1.5 Myelin oligodendrocyte glycoprotein (MOG) antibody y mielitis 
La myelin oligodendrocyte glycoprotein (MOG) es una proteina transmembrana 
localizada en la vaina más externa de la capa de mielina. Esta proteína posee 
propiedades encefalitogénicas (Linington C, et al. 1988). 
Actualmente y gracias a la utilización de técnicas de "Cell Based Assay", se 
puede detectar el anticuerpo contra la proteína MOG (MOG-ab) en su estado 
conformacional. Gracias a ello, los MOG-ab se han descrito fundamentalmente 
en pacientes pediátricos con ADEM así como en pacientes adultos diagnosticados 
de NMOSD (Baumann et al. 2015; Sato DW, et al. 2014; Höftberger R, et al. 2015). Entre 
estos últimos las frecuencias se han observados hasta en casi el 10%. 
Los pacientes con NMOSD que presentan MOG-ab se caracterizan por ser más 
jóvenes al inicio de la enfermedad, tener una predominancia del sexo femenino y 
un comienzo de los síntomas en forma de NO y LETM de manera simultánea, 
comparado con aquellos pacientes con AQP4-ab o sin anticuerpos. Además, estos 
pacientes tendrán una enfermedad sin tendencia a la recidiva así como un mejor 
pronóstico funcional. Los pacientes con MOG-ab en suero presentan además una 
localización de la lesión más frecuente a nivel lumbar. Estos pacientes presentan, 
además, una tendencia a la resolución de la lesión medular objetivada por RM 
(Sato DW, et al. 2014; Höftberger R, et al. 2015). 
Entre el 6 y el 7,5% de los pacientes diagnosticados de un primer episodio de 
LETM presentan MOG-ab en suero (Sato DW, et al. 2014; Höftberger R, et al. 2015; Hyun 
JW, et al. 2015). Un reciente estudio observó que estos pacientes eran más jóvenes y 
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con menor número de recidivas comparado con los pacientes con AQP4-ab. Los 
pacientes con MOG-ab tenían un mejor pronóstico funcional que los pacientes sin 
AQP4-ab ni MOG-ab en suero. Finalmente, una característica de estos pacientes 
fue la afectación de todos los segmentos medulares objetivada en la RM espinal 
(Höftberger R, et al. 2015). 
 
2. HIPÓTESIS Y OBJETIVOS 
Este estudio parte de la hipótesis de que existirían características específicas a 
nivel epidemiológico, clínico, de LCR y radiológico en pacientes con un primer 
episodio de MTAI que orientarían a predecir la conversión de estos pacientes a 
EM. Además, existirían algunas de ellas que ayudarían a identificar aquellos 
pacientes con evolución más tórpida y peor pronóstico funcional. La 
identificación de estas variables sería de vital interés para la realización de 
futuros ensayos terapéuticos en este tipo de pacientes. 
Por otra parte, creemos que en pacientes con un primer episodio clínico de LETM 
existirían diferencias en las características epidemiológicas, clínicas, en LCR y 
radiológicas que permitirían su clasificación en los distintos subgrupos 
etiológicos. Además, el hallazgo de de estas características permitiría identificar 
aquellos pacientes que presentan un peor pronóstico en toda la cohorte y más 
específicamente en cada unos de los subgrupos etiológicos. 
Finalmente, pensamos que una proporción de pacientes con un primer episodio 
de LETM seronegativa para AQP4-ab presentarían MOG-ab y podrían presentar 
hallazgos epidemiológicos, clínicos, de laboratorio y radiológicos diferentes de 
aquellos que son negativos para MOG-ab. 
Los objetivos del estudio fueron, a) describir el ratio de conversión a EM y las 
variables asociadas a conversión en pacientes diagnosticados de MTAI según los 
criterios establecidos por la TMCWG, b) analizar los factores pronósticos y la 
discapacidad a largo plazo en pacientes con un primer evento de mielitis que 
cumplan los criterios de la TMCWG, 3) evaluar el espectro clínico de aquellos 
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pacientes que presentan un primer evento de LETM por RM y evaluar el 
pronóstico funcional de estos pacientes, 4) evaluar la frecuencia de MOG-ab en 
pacientes con un primer evento LETM seronegativa para AQP4-ab y describir las 
características clínicas de estos pacientes en comparación a aquellos que no 
presentan MOG-ab en suero. 
 
3. METODOLOGÍA 
El trabajo se divide en tres estudios; 1) Mielitis transversas agudas idiopáticas, 
2) Mielitis longitudinalmente extensas y 3) MOG-ab en mielitis longitudinalmente 
extensas  
La metodología de los dos primeros estudios es similar. Brevemente, se 
recogieron retrospectivamente los datos epidemiológicos (edad, género, estación 
de comienzo), clínicos (afectación de esfínteres, discapacidad al comienzo y al 
final del seguimiento), de LCR (BOC, índice IgG células, proteínas) y de RM 
craneal y espinal (número de lesiones localización, longitud de las lesiones, 
captación de gadolínio) de los enfermos que cumplían los criterios establecidos 
por la TMCWG 2002 entre los años 1989 y 2011 en el Hospital Universitario de 
Bellvitge. De ellos, se excluyeron aquellos que fueron positivos para AQP4-ab en 
suero. De la misma manera, se seleccionaron aquellos pacientes con un primer 
episodio de LETM independientemente de su enfermedad subyacente entre los 
años 1993 y 2011. Se definió LETM como sigue; 1) desarrollo de los síntomas 
durante no más de 21 días, 2) Hiperintensidad T2 en tres o más segmentos 
vertebrales contiguos, 3) síntomas bilaterales motores o sensitivos con o sin 
afectación de esfínteres, 4) RM cerebral disponible, 5) se excluyeron aquellos con 
irradiación espinal previa, compresión medular, historia de enfermedad 
neurológica y síntomas atribuidos a otra región distinta a la médula espinal. 
Para estos pacientes con LETM se definieron ocho variables etiológicas; 1) EM 
(definida y probable) de acuerdo con los criterios de Poser o McDonald, 2) 
ADEM, 3) NMO,
 
4) mielopatía parainfecciosa, definida por una prueba 
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serológica o de PCR de infección reciente en sangre o LCR, 5) enfermedad 
sistémica, definida por los criterios modificados de la American Rheumatism 
Association for Systemic Lupus Erythematosus y los criterios Vitali et al para 
Sjögren’s syndrome,  6) infarto medular, definido por el comienzo agudo y 
anormalidades en la intensidad de la señal por RM correspondientes a un 
territorio vascular espinal sin otra etiología, 7) etiología tumoral o "tumor-
related",
 8) fístula dural, 9) idiopática con la presencia de ≥3 segmentos 
vertebrales demostrados en secuencias T2 por RM sin otra causa identificada tras 
un exhaustivo estudio. 
Para la evaluación de la discapacidad se utilizó la modified Rankin Scale (mRS) 
con una categorización entre dos grupos: mRS < 2 y ≥ 2, para distinguir entre 
pacientes con buen y mal pronóstico, respectivamente. Los pacientes que 
conviertieron a EM fueron evaluados mediante la Expanded Disability Status 
Scale de Kurtzke (EDSS).  
El tercer estudio es un estudio multicéntrico en el cual se incluyeron todos los 
pacientes diagnosticados de un primer episodio de LETM con AQP4-ab negativos 
en los hospitales universitarios de Toulouse, Lyon (Francia) y el Bellvitge 
(España). Los datos se introdujeron de manera prospectiva entre Enero del 2005 
y Diciembre del 2014 en la "Database adapted from the EDMUS system" (Eugène 
Devic European Network, EDEN). Los criterios de inclusión se detallan en la 
Tabla 2.  
Tabla 2. Criterios de inclusión para LETM seronegativa para AQP4-ab 
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Se recogieron, al igual que en los dos primeros estudios, las variables 
epidemiológicas, clínicas, de laboratorio y de RM espinal y craneal. Se 
determimó los AQP4 y MOG-ab en los centros del Institut d'Investigació 
Biommèdica August Pi i Sunyer (IDIBAPS) de Barcelona y en el Centro de 
investigación de neurociencias de Lyon, como ya ha sido descrito (Höftberger R, et 
al. 2015; Marignier R, et al. 2013). Los pacientes se categorizaron en dos grupos EDSS 
≤2,5 and EDSS ≥ 3 para la evaluación del pronóstico funcional. 
Todos los estudios obtuvieron la aprobación de los comités de ética de los 
diferentes hospitales. 
Para las variables categóricas se utilizaron X
2 
o test de Fisher, para variables 
cuantitativas U de Mann-Whitney o t-test, según procediese. El análisis de las 
variables pronósticas se llevó a cabo con modelos de regresión logística y los 
análisis de supervivencia con análisis de Cox. Se utilizó el programa SPSS 
(versión 20.0) para los dos primeros estudios y STATA (64-bits) para el tercer 
estudio. 
 
4. RESULTADOS 
4.1 Primer estudio. Mielitis agudas transversas idiopáticas: pronóstico y 
conversión a Esclerosis Múltiple. 
Se incluyeron 87 pacientes y dos de ellos fueron excluidos por presentar AQP4-
ab. Ambos pacientes convirtieron a NMO. Tras un seguimiento de 2,9 años, el 
13% de los 85 pacientes que cumplieron estrictamente los criterios de la TMCWG 
2002 convirtieron a EM y el 87% permanecieron como MTAI. Se observó una 
LETM en el 30,6% de los pacientes y únicamente se objetivaron recidivas 
espinales en los pacientes del grupo de EM. 
Al final del seguimiento, el 37% de los pacientes presentaron un mal pronóstico 
(mRS ≥ 2) y 9,4% fueron incapaces de deambular de manera independiente. 
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Los pacientes que convirtieron a EM presentaron un inicio de los síntomas a una 
edad más joven. Además, observamos que el 33% de los pacientes con una MTAI 
que presentaron BOC en LCR convirtieron a EM comparado con el 2% sin BOC, 
y que el valor predictivo negativo de la combinación de BOC negativas e índice 
IgG ≤ 0,7 en LCR era del 100%. 
Los factores asociados a un mal pronóstico funcional fueron el presentar 
incontinencia urinaria y LETM por RM espinal al inicio del estudio. 
 
4.2 Segundo estudio. Espectro etiológico y pronóstico de mielitis 
longitudinalmente extensas. 
Tras la inclusión de 72 pacientes que cumplieron criterios de LETM y un 
seguimiento de 34 meses, la forma idiopática fue la etiología más frecuente 
(30,5%) seguido de la EM (25%). La etiología parainfeciosa se identificó en el 
14,9% , Lupus Eritematoso Sistémico y Síndrome de Sjogren en el 12,2%. Otras 
etiologías como el infarto espinal y NMOSD se observaron en tres pacientes, y 
ADEM, fístula dural, y " tumour-related LETM" en dos pacientes cada uno. 
Los pacientes con EM se caracterizaron por un inicio de los síntomas a edades 
más tempranas, con una menor discapacidad inicial y una menor frecuencia de 
afectación de esfínteres en comparación al resto de etiologías. Además, la 
presencia de BOC y una localización cervical en la RM espinal se relacionó con 
el diagnóstico de EM. 
Al final del estudio, el 72,2% de los pacientes tenían un mRS ≥ 2, siendo la forma 
idiopática la más discapacitante. EL presentar una mayor discapacidad al inicio 
de los síntomas y una mayor edad fueron factores predictores de mal pronóstico 
funcional. 
 
4.3 Tercer estudio. Anticuerpos anti-MOG en myelitis longitudinalmente 
extensa seronegativa para AQP4-ab: implicaciones clínicas y pronósticas 
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En el presente estudio, se incluyeron 56 pacientes diagnosticados de LETM 
seronegativa para AQP4-ab. Observamos que el 23% de los pacientes 
presentaron MOG-ab en suero. Los pacientes con MOG-ab positivos presentaron 
un inicio de síntomas más temprano, una mayor predisposición a NO y un mejor 
pronóstico funcional que aquellos con MOG-ab negativos. Además, una mayor 
proporción de pacientes con MOG-ab presentaron pleocitosis en LCR y una 
resolución completa de la lesión en la RM espinal comparado con los MOG-ab 
negativos. 
Se objetivó que una mayor discapacidad al inicio del estudio se relacionó con 
peor pronóstico funcional y la presencia de MOG-ab se relacionó con un buen 
pronóstico funcional. Los pacientes con MOG-ab presentaron mayor riesgo de 
presentar NO y, por tanto, mayor probabilidad de convertir a NMO.  
Al final del estudio, 10,7% convirtieron a NMO, 1,8% a EM, 16,1% presentaron 
recidivas de LETM y el 71,4% de los pacientes permanecieron como LETM 
monofásica. 
 
5. DISCUSIÓN 
5.1 Mielitis trasversa aguda idiopática 
En el presente estudio observamos que únicamente el 9,4% de los pacientes 
fueron incapaces de deambular de manera independiente a diferencia de otros 
estudios donde la proporción es mayor (de Seze J, et al. 2005). Una de las posibles 
causas de esta diferencia puede ser que los pacientes fueron visitados en un 
centro de referencia produciéndose así un sesgo de selección. Una mayor 
discapacidad al inicio de los síntomas y la presencia de LETM se han 
relacionado a un peor pronóstico funcional en pacientes que cumplen los 
criterios de la TMCWG 2002 (de Seze J, et al.2005; Li R, et al 2011; Bruna J, et al.2006). 
En nuestro estudio, una mayor discapacidad al inicio de los síntomas se asoció a 
un peor pronóstico aunque perdió significación en el análisis multivariante. 
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La proporción de pacientes que convierten a EM en nuestro estudio es similar a 
lo descrito en otros estudio bajo los criterios de la TMCWG. Destacamos la 
utilidad de los parámetros de LCR en la predicción de conversión a EM ya que 
aquellos pacientes que no presenten ni BOC ni un índice IgG anormal en LCR 
muy probablemente no convertirán a EM. Al igual que lo descrito en otros 
estudios, el presentar los síntomas a edades menores se asoció a conversión a EM 
(Ruet A, et al. 2011). 
En nuestra cohorte, dos pacientes presentaron un episodio de LETM y fueron 
exluidos al presentar AQP4-ab. Ambos pacientes convirtieron a NMO. Otros 
estudios señalan una mayor proporción de conversión a NMO tras un primer 
episodio de LETM (Chang KH, et al. 2013; Hyun JW, et al. 2014). De los pacientes que 
estrictamente cumplieron los criterios de la TMCWG, ninguno de ellos desarrolló 
una NMO, indicando que es una entidad rara en nuestro medio. Las técnicas de 
detección de los AQP4-ab, los criterios de inclusión de LETM así como las 
poblaciones genéticas incluidas entre los diferentes estudios pueden ser las 
causas de estas discrepancias. 
En el presente estudio, nos llama la atención que únicamente aquellos pacientes 
que convierten a EM presentarán recidivas espinales. En nuestra opinión, es 
posible que diferentes mecanismos patogénicos aún no conocidos (ej, infecciones, 
anticuerpos patogénicos) sean los responsables de la presentación de LETM en 
forma monofásica. 
 
5.2 Mielitis longitudinalmente extensas 
La forma idiopática fue la etiología más frecuente al igual que se ha objetivado 
en diferentes estudios mediterráneos que describen frecuencias de entre el 40 y el 
86% (Sepúlveda M, et al. 2013; Iorio R, et al. 2013). Otros estudios han descrito 
frecuencias menores (Kitley J, et al. 2013). Algunas causas que pueden explicar estas 
discrepancias son las diferencias entre los criterios de inclusión (algunos 
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pacientes incluidos presentaron episodios previos de afectación desmielinizante 
del SNC) o las diferencias proporciones en las poblaciones étnicas incluidas. 
Pensamos que la alta prevalencia de EM en comparación a NMO en nuestra 
población puede ser el motivo por la cual la EM sea la segunda causa de LETM. 
Destacamos la edad temprana de comienzo de síntomas, la afectación cervical y 
la presencia de BOC en LCR como variables que nos deben hacer pensar en EM 
ante un primer episodio de LETM. 
Como ya hemos mencionado, la presencia de NMOSD es rara en nuestra 
población. Aunque el test de AQP4 no se realizó a toda la población, ningún 
paciente presentó sucesivas recidivas de NO ni mielitis tras un seguimiento de 
tres años y por tanto no convirtieron a NMOSD. 
Al final del estudio, el 72,2% de los pacientes tuvieron un mRS ≥ 2. Observamos 
una tendencia hacia un mejor pronóstico entre los pacientes cuya causa fue 
parainfecciosa como ha sido descrito en la literatura. Las mielitis secundarias a 
AQP4-ab o infartos medulares se han relacionado con un peor pronóstico (de Seze 
J, et al. 2001; Debette S, et al. 2009). Sin embargo, no fue posible comparar estos 
grupos dado el reducido número de pacientes  
En nuestro estudio, una mayor discapacidad al comienzo de los síntomas y una 
mayor edad fueron factores de mal pronóstico funcional. El presentar una mayor 
discapacidad al comienzo de los síntomas se ha relacionado a un peor pronóstico 
en estudios centrados fundamentalmente ene LETM. Sin embargo, la mayoría de 
los pacientes incluidos en estos estudios presentaban una LETM idiopática y es 
por ello que no podemos directamente compararlos (de Seze J, et al. 2005; Sepúlveda 
M; et al. 2013). 
 
5.3 Myelin oligodendrocyte glycoprotein en mielitis longitudinalmente extensas 
Observamos que el 23% de los pacientes que presentaron un primer episodio de 
LETM seronegativa para AQP4-ab tenían MOG-ab en suero. Este porcentaje es 
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mayor que lo observado en la literaturas donde se han descrito frecuencias de 
hasta el 7,5% (Hyun JW, et al. 2015) La falta de consenso en la aplicación de 
criterios de LETM entre los diferentes estudios y el distinto perfil autoinmune que 
puede existir entre etnias, al igual que en los NMOSD y AQP4-ab, son las causas 
más probables de estas discrepancias (Marignier R, et al. 2013). 
Al igual que en algunos experimentos en modelos animales donde se ha 
observado una resolución completa de las lesiones cerebrales después de dos 
semanas de la inmunización con MOG-ab, observamos que los pacientes con 
MOG-ab presentaron una resolución completa de las lesiones por RM espinal en 
comparación a aquellos que eran seronegativos para dicho anticuerpo (Saadoun S, 
et al. 2014). 
Objetivamos que una mayor proporción de pacientes MOG-ab positivos 
presentaron pleocitosis en LCR, lo cual podría indicar una infección subyacente, 
al igual que ha sido observado en otras enfermedades con MOG-ab como el 
ADEM (Baumann M, et al. 2015). 
El presentar una mayor discapacidad al inicio del estudio fue el único factor 
clínico asociado a un mal pronóstico funcional. Como se ha dicho con 
anterioridad, este dato se ha objetivado en algunos estudios que incluyen LETM 
(de Seze J, et al. 2005; Sepúlveda M, et al. 2013). Por otra parte, la presencia de MOG-ab 
en suero se asoció a un mejor pronóstico. Este últimos dato debe considerarse 
como preliminar y estudios prospectivos deben realizarse para confirmar 
nuestros resultados. 
Por último, nos gustaría resaltar que cuatro pacientes presentaron un fenotipo 
clínico de NMO pero que sin embargo eran MOG-ab positivos. Este dato 
cuestiona la correcta clasificación de este tipo de pacientes bajo un fenotipo 
clínico y abre la puerta a una clasificación biológica en forma de "astrocitopatía" 
o "aquaporinopatía" y "oligodendrocitopatía" o "mogpatía",  como ya han 
señalado otros autores (Zambil SS, et al. 2015). 
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6.CONCLUSIONES 
Al final del primer estudio, el 37,6% de los pacientes diagnosticados de MTAI 
tuvieron un mRS ≥ 2 y el 9,4% no fueron capaces de deambular de manera 
independiente. El pronóstico funcional en los pacientes con MTAI fue peor en 
aquellos que presentaron afectación de esfínteres o LETM por RM espinal al 
inicio de los síntomas. 
Objetivamos que hasta el 13% de los pacientes con diagnosticados de MTAI bajo 
los criterios de la TMCGW convirtieron a EM y que una edad de presentación 
menor se asocia a conversión a EM. 
Hasta el 72,2% de los pacientes afectos de un primer episodio de LETM 
presentarán un mRS ≥ 2. Los factores que se asociaron a un peor pronóstico en 
pacientes con un primer episodio de LETM fueron una mayor discapacidad y una 
mayor edad al inicio de los síntomas. Mientras la causa más frecuente de LETM 
es la idiopática en nuestro medio, el diagnóstico de NMOSD entre estos pacientes 
es poco frecuente.  
Los MOG-ab se encuentran hasta en el 23% de los pacientes que presentan un 
primer episodio de LETM seronegativa para AQP4-ab. Estos pacientes 
representan un subgrupo con hallazgos distintivos representados por una menor 
edad de presentación, mayor predisposición a NO y un mejor pronóstico 
funcional. 
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ABBREVIATIONS 
Acute transverse myelitis (ATM) 
Multiple Sclerosis  (MS) 
Cerebrospinal fluid (CSF). 
Idiopathic ATM (IATM) 
Transverse Myelitis Consortium Working Group (TMCWG). 
Magnetic Resonance Imaging (MRI) 
Neuromyelitis optica (NMO) 
Aquaporin 4 antibody (AQP4-ab) 
Acute partial transverse myelitis (APTM)  
Acute complete transverse myelitis (ACTM). 
Longitudinal extensive transverse myelitis (LETM) 
NMO spectrum disorders (NMOSD) 
Oligoclonal bands (OCB) 
Clinically isolated syndrome (CIS) 
Acute demyelinating encephalomyelitis (ADEM), 
Plasma exchange (PLEX)  
Central Nervous System (CNS) 
Acute transverse myelitis associated with Multiple Sclerosis (ATM-MS). 
Optic neuritis (ON) 
Myelin oligodendrocyte glycoprotein (MOG) 
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Myelin oligodendrocyte glycoprotein antibody (MOG-ab) 
Expanded Disability Status Scale (EDSS) 
Sjogren's Syndrome (SS) 
Systemic lupus erythematosus (SLE) 
Behcet's disease (BD) 
modified Rankin Scale (mRS) 
Standard deviation (SD) 
Interquartile range (IQR) 
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1. INTRODUCTION 
1.1 Historical aspects of acute transverse myelitis  
1.1.1 First reports  
Bastian HC (1837-1915, pathologist at St Mary's Hospital, London) was 
largely responsible for establishing and classifying the concept of transverse 
myelitis into two different nosologies; acute inflammatory myelitis and non- 
inflammatory acute myelitis. The former, he thought to be due to an 
infectious or an allergic mechanism, and the latter due to "blood changes and 
toxins often associated with feeble cardiac action, which may well act as 
causes of thrombosis in vessels of the spinal cord”.1,2 Vascular myelopathy 
was later confirmed by William Spiller when he reported the case of a patient 
who developed a tetraplegia within 24 hours after lifting 100-Ib. Spinal cord 
autopsy revealed a blood clot in the anterior spinal artery and a diagnosis of 
myelitis due to thrombosis was established.3  
Spinal cord inflammation due to Smallpox vaccination was reported 
afterwards. Some authors hypothesized that a state dependent host 
susceptibility could be the initial cause of an immune mediated neurologic 
disease.4 However, Frank Ford, in 1928, suggested that myelitis could be 
explained as a post infectious disease rather than as a direct attack of the 
virus to the spinal cord.5 Over the next decades, several reports of post 
infectious myelitis due to measles or rubella were reported.6-8 It was not until 
1948 when the term “transverse myelitis” was proposed by an English 
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neurologist who described a case of rapidly progressive paraparesis with 
thoracic sensory level, occurring as a post infectious complication of 
pneumonia.9  
 
1.1.2 Evolving concepts  
Initial studies which established guidelines for diagnosis and prognosis of 
acute transverse myelitis (ATM) in a relatively large number of patients were 
reported in the seventies.10,11 The authors’ defined ATM as a progressive 
spinal cord dysfunction over a period of less than four weeks, with a well 
defined upper sensory level and without any compressive aetiologies or 
previous illness. At the end of the 20th century several criteria had already 
been proposed in order to clarify the ATM definition.12-14 Others tried to 
identify factors related to functional outcome or to Multiple Sclerosis 
conversion (MS) after a first episode of ATM.15-17 
The antecedent of the current criteria for ATM was proposed by the de Seze J, 
et al. who aimed to assess the different aetiologies comprising this entity as 
well as to report the prognosis.18 Diagnosis criteria for ATM included acute or 
sub acute motor or sensory symptoms with or without sphincter dysfunction, 
a well defined sensory upper level, length of symptoms over no more than 3 
weeks sustained at least 48 hours and no evidence of neither spinal 
compression by radiological imaging nor known history of neurological 
disease or symptoms. In this work, authors concluded that aetiologies could 
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be differentiated on the basis of clinical, brain and spinal cord imaging 
studies and cerebrospinal fluid (CSF). Most of the cases presenting with ATM 
were belong to the MS group (43%). Systemic disorders made up 16,5% of 
patients, spinal cord infarction 14%, infectious diseases 6%, delayed 
radiation myelopathy 4% and myelitis of unknown origin 16,5 %. 
Soon thereafter, the current criteria for idiopathic ATM (IATM) were 
proposed by the Transverse Myelitis Consortium Working Group 
(TMCWG).19 
 
1.2. Acute transverse myelitis 
1.2.1 Transverse Myelitis Consortium Working Group Criteria 
1.2.1.1 Proposed criteria 
In 2002, the TMCWG proposed the diagnostic criteria for IATM in order to 
delimit and unify this group of patients (Figure 1).19 
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Figure 1. Idiopathic acute transverse myelitis criteria by the Transverse 
Myelitis Consortium Working Group. (From the TMCGW 2002 criteria)19 
 
1.2.1.2 Limitations in the current criteria  
The TMCWG authors themselves noted several shortcomings regarding the 
elicited criteria. 
Firstly, evidence of inflammation within the spinal cord was needed. The 
usefulness of Magnetic Resonance Imaging (MRI) and CSF in order to detect 
inflammation within the spinal cord was proposed by the authors as spinal 
cord biopsy was not a practical option. Gadolinium enhancement is a well 
known marker of blood barrier disruption,20 and according to the authors, it 
should be present in patients with “definite IATM”. Regarding CSF, 
pleocytosis (>5 cells/ml) or abnormal IgG index (>0,7) should be present, as 
well. In those patients who fulfill the IATM criteria with the exception of the 
inflammatory criteria, an MRI and lumbar puncture should be performed 
between two and seven days after the onset of symptoms. Nonetheless, the 
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spinal cord MRI of some patients fulfilling these criteria does not show 
gadolinium enhancement, having high signal T2-weight intensity instead. If it 
is not possible to demonstrate any evidence of CSF inflammation, patients 
should be classified as “possible IATM”.  
Secondly, the authors suggested that patients who develop symptoms over a 
period of less than four hours should be presumed to have an ischemic cause. 
However, as the authors pointed out, patients with ischemic myelitis could 
fulfill the time criterion for IATM and, therefore, they would be included.21 
Moreover, progressive myelopathies lasting less than 21 days could be 
included within the temporary range proposed by the TMCWG. The authors 
emphasized hereditary myelopathies, spinal cord tumors, dural 
arteriovenous fistules, or chronic forms of MS as main causes of progressive 
myelopathies.22-24 TMCWG also noted that clinical history or gadolinium 
enhancement on MRI of spinal tumours could not differentiate them from 
IATM in some cases. Thus, they suggested starting with corticoids and to 
perform an imaging test shortly thereafter. If there is no decrease of 
gadolinium enhancement a biopsy should be done. Considering inflammatory 
myelopathies, some of them could clinically evolve over more or less than the 
time range proposed and they would be dismissed. 
Thirdly, ATM could be the first symptom of a subsequent Neuromyelitis 
optica (NMO),25 and a first episode of IATM could not be differentiated from 
NMO based on the current criteria. We must note that TMCWG proposed the 
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criteria before the aquaporin-4 antibody (AQP4-ab) marker to NMO was 
described.26 
Finally, some authors have also criticized the proposed TMCWG criteria. Scott 
TF, et al. underlined the lack of distinction between acute partial (APTM) and 
acute complete transverse myelitis (ACTM). As the natural history between 
ACTM and APTM is significantly different, these authors defined alternative 
criteria to the current criteria proposed by the TMCGW.27 They pointed out 
that ACTM refers to a complete o near complete disruption of function at the 
spinal cord level meanwhile APTM would be characterized by a patchy or 
grossly asymmetrical spinal cord dysfunction. The former would be 
associated to longitudinal extensive transverse myelitis (LETM) and would 
be related to the NMO spectrum disorders (NMOSD). The latter would be 
related to MS conversion, less frequency of oligoclonal bands (OCB) in CSF 
and less chance of relapse in the form of ATM.28 The main difference between 
the Scott criteria and the TMCWG criteria is that in the former the evidence of 
CSF or MRI inflammation within the spinal cord is not mandatory compared 
to the latter. The authors also highlighted the lack of usefulness of the 
TMCWG criteria for characterizing patients from the outpatients neurology 
clinics. The criteria would exclude mild cases with APTM due to the fact that 
some of these patients will not undergo CSF or MRI in the clinical setting. 
Moreover, similar CSF or MRI results related to an inflammatory aetiology 
could be found between APTM and ACTM when prognosis and risk of MS 
conversion are significantly different between these two entities. Recently, 
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diagnosis and treatment guidelines of transverse myelitis have also 
emphasized the importance of classifying patients according to the complete 
or partial status  in order to better identify the underlying aetiology and the 
relapse risk.29  
 
1.2.2 Epidemiology  
Reliable population-based studies estimating the incidence of ATM are 
limited. Two classical studies carried out in Israel and Albuquerque (New 
Mexico) yielded annual incidences for ATM ranging between 1,3 and 4,6 
cases per million, respectively.12,14 In the latter, the authors observed that 
IATM incidence was approximately 1,0 per million (21% among the whole 
ATM cohort). One study from the Kaiser Permanente Northern California 
(KPNC) patient database described an incidence of 3,1 per million (2,6-3,6 
95% confidence interval).30 Most recently, a multiethnic retrospective cohort 
study conducted by the same organization (KPNC) was performed in order to 
evaluate the incidence of clinically isolated syndrome (CIS) in a population of 
9,0 million inhabitants. Herein, myelitis was observed in 34% of CIS cases (all 
ethnics included), corresponding to 22,6 per million in terms of annual 
incidence in Caucasians.31 The only modern study focuses on IATM was 
carried out by a group from North Canterbury, New Zealand, in 2009. The 
overall incidence of ATM was 24,6 per million, decreasing to 6,2 per million 
in the group of  IATM.32 
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Regarding gender, ATM was classically observed equal between men and 
women (ratios 1:1).10,11,33 However, over the last few years, a trend towards 
female predominance has been observed in IATM studies fulfilling the 
TMCGW criteria (between 66% to 86%),32,34,35 although some of them still 
disclose an equal proportion of cases.36,37 Population-based health databases 
studying incidence of CIS reported that up to 65% of patients who develop 
ATM as a first manifestation of CIS were female.31 
Bimodal peaks of distribution have been shown in older studies; ages 
between 10–19 and 30–39 years.12-14 It seems that the mean age of the onset 
of the symptoms in patients with IATM ranges from 35 to 40 years, as has 
been observed in recent studies.32,34,35,37 Only one study reported older ages 
of IATM with a mean of 59 years.36  
 
1.2.3 Clinical management  
The different ATM criteria applied through the last decades will mark clinical 
and prognostic aspects reported to date.  
Transverse myelitis is characterized by a focal inflammation within the spinal 
cord resulting in acute and subacute clinical manifestations due to neural 
dysfunction of motor, sensory and autonomic pathways. In Figure 2, the 
clinical presentation of spinal cord disorders are represented.38 
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Figure 2. Clinical presentation of spinal cord disorders. (From Jacob A, et 
al.)38 
 
 
Prodromal symptoms often appears as the prelude of ATM within four weeks 
before the onset of ATM.10-14,33,39 Studies carried out after the setting of 
TMCWG criteria point to a history of nonspecific previous infection or fever 
in 7,3-40% of patients,37,40-42 and back pain up to 50%.37 
Paresthesias or the sensation of numbness, both in the distal part of the 
lower extremities and the abdomen are usually described as the initial 
manifestation in ATM. A sensory level is documented in most of the cases and 
the thoracic level is affected in 50% to 80 % of patients.10,32 Moreover, 
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studies performed after the TMCGW criteria have showed a wide range of 
variability in sensory impairment ranging from 17,5% up to 100%.34,40,43 
Regarding pyramidal tract symptoms, a progressive ascending paraparesia 
starting in the lower limbs is usually observed and, although more 
uncommon, it could occasionally involve the arms. Spinal shock has being 
reported as an initial disabling symptom, as well. This severe state is 
characterized by lower limb arreflexia, flaccid paraparesia and spasticity 
developing 10 days after the onset.11,13 The first study performed under 
TMCWG criteria observed that 37,8% of patients developed spinal shock 
after the first episode of ATM.34 Tonic spasticity may follow the initial 
weakness and tonic involuntary spasms are often explained by patients. 
Motor symptoms in ATM range from 26,7% to 78%.34,40 
Sphyncter dysfunction is a prominent symptom in ATM and is observed in a 
high proportion of patients (up to 94% in some series).44 It comprises of a 
wide spectrum of symptoms; urge incontinence, incomplete retention, 
voiding difficulty or constipation are the main symptoms.44,45 In the latest 
studies, between 26% and 67% of patients are reported to have sphincter 
dysfunction at the onset of ATM.37,43 Sexual dysfunction  is also observed in 
patients who develop an episode of ATM and includes erectile or ejaculatory 
dysfunction and difficulty to reach orgasm.46 
It is usually observed that symptoms peak within the first ten days from 
onset. During this time, half of the patients are unable to develop any 
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movement in lower limbs and almost all patients present some degree of 
sensory or bladder dysfunction. However, symptoms may progressively 
worsen up to the first 21 days. These observations may vary depending on 
the criteria established.13,16,37,39,43 
A moderate variety of depression could be a major neuropsychiatric 
symptom observed in patients with ATM (30%), although others such as 
anxiety, somatoform or neurotic disorders have also been reported.47,48 Some 
authors have remarked on the importance of identifying depressive patients 
as suicide could represent up to 60% of deaths.49 Moreover, cognitive 
impairment has been suggested in one study where a fifth of patients who 
suffer from ATM scored less than 23 in the Minimental Score Examination.47 
Finally, some patients may develop acute respiratory failure during the 
course of the disease due to upper cervical and brainstem affection. This 
affection may be potentially lethal for patients with ATM.40 
 
1.2.4 Diagnosis 
The diagnostic approach for evaluating patients with acute myelopathies 
specified herein is based on the TMCWG criteria. The differential diagnosis of 
ATM is wide and identification of the cause will inform us about the future 
clinical course as well as the prophylaxis treatment against future 
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neurological episodes. (Figure 3 shows the diagnostic  algorithm proposed 
by the TMCWG).19 
Figure 3. Diagnostic algorithm proposed by the TMCWG. (From the TMCWG 
2002 criteria)19 
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Before performing further additional medical tests, recognition of the clinical 
syndrome is the first step. The time scale of hours to days of neurological 
deficits, symmetric or asymmetric presentation along with a well defined 
truncal sensory level should promptly lead us to a spinal cord syndrome. 
Central signs of nervous system dysfunction such as hiperreflexia or Babinski 
sign are classically found in spinal cord syndromes. However, a flaccid 
weakness or global arreflexia could be observed as being part of spinal shock. 
Ruling out compressive lesion is the priority in patients who develop a spinal 
cord syndrome. A spinal cord MRI with gadolinium contrast agent of the 
whole spinal cord should be performed within four hours from the onset of 
symptoms. Myelography Computerized Tomography is also recommended as 
a means to dismiss structural cause if no MRI techniques are available. As 
soon as the cause of compression is detected, neurosurgical evaluation 
should be carried out. 
A lumbar puncture should be performed in order to document inflammation 
as a further step. The absence of pleocytosis or abnormal IgG index along 
with the absence of gadolinium enhancement in the spinal cord MRI leads to 
a non inflammatory aetiology. However, if any inflammatory data are 
present, a subsequent step is to determine whether demyelination extends 
beyond the spinal cord. Acute demyelinating encephalomyelitis (ADEM), MS 
and NMO are the main disorders to investigate and patients should undergo a 
brain MRI with gadolinium and visual evoked potentials. 
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If inflammation is confined to the spinal cord, ATM diagnosis is established 
and the underlying aetiology must be investigated. Medical, social and travel 
history as well as general examination are essential to identify the underlying 
disease (Figure 4).19 
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Figure 4. Work- up in suspected ATM. (From the TMCWG 2002 criteria)19 
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1.2.5 Treatment 
1.2.5.1 Goals of the treatment 
ATM is a potentially severe disease with high rates of functional disability. 
Therefore, urgent treatment after the onset of symptoms is mandatory in 
order to halt the progression and initiate recovery from spinal cord 
inflammation.50 
1.2.5.2 Corticosteroids 
There are no placebo controlled trials and only few have evaluated the use of 
corticoids in patients presenting with ATM or spinal cord injury.51,52 Thus, 
evidence of the use of these agents in myelitis derives from MS studies. Based 
assessment of corticoids in MS patients points out that corticoids shorten the 
recovery from attacks of MS without demonstrating long term benefits in the 
course of the disease.53 Although common regimens use intravenous 
methylprednisolone (1g/24 h  * 3 or 5 days), there is evidence that oral 
methylprednisolone could improve clinical and imaging parameters in a 
similar manner.54,55 
Conflicting results have been reported in regards to corticoid treatment in 
ATM. Case series or retrospective studies have shown to be beneficial in 
pediatric populations.56,57 The only prospective controlled based study 
performed in 21 patients (range of age between 12 and 70 years) revealed an 
apparently beneficial role of methylprednisolone in ATM (67% of patients in 
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the non- treated and 33% in the treated arm had poor outcome, 
respectively). However, such differences did not reach statistical 
significance.51 Only Class IV existed concerning the utility of corticoids in 
treating ATM under the most recent based guidelines. It is concluded that 
although there is no sufficient evidence to determine the utility of 
corticosteroids in acute attacks of TM, they could be administrated in the 
clinical practice to hasten recovery, reduce disease activity and restore 
neurologic function.29 
1.2.5.3 Plasma exchange  
Plasma exchange (PLEX) has been proved to be a useful treatment in several 
antibody-mediated diseases. It has been implied in several immunological 
roles such as the non specific removal of toxins, antigens or humoral 
factors.58 Meanwhile PLEX seem to have a potential beneficial effect in 
relapsing forms of neuroimmunological diseases such as MS or NMO,59,60 it is 
not the case in progressive forms.61 
A randomized double blind, placebo- controlled class II trial concluded that 
PLEX is a possible effective treatment for patients with acute Central Nervous 
System (CNS) demyelinating diseases that do not respond to a previous 
corticosteroids line.62 However, this study did not conclude if PLEX was more 
or less effective in ATM patients due to the heterogeneity of the patients 
included. Recently, The Therapeutics and Technology Assessment 
Subcommittee of the American Academy of Neurology supported this 
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strategy in patients suffering ATM with a C level of evidence.63 Others have 
noted that an early initiation of PLEX, better improvement on discharge, 
being male or preserved reflex increase the likelihood of improvement in 
response to PLEX in patients with CNS demyelinating diseases, including 
transverse myelitis.64,65 Finally, only one retrospective un-controlled study 
regarding treatment has been carried out in patients who fulfill the current 
IATM criteria. This study included 122 patients with IATM and suggested 
that patients who do not reach the American Spinal Injury Association (ASIA) 
A level of disability at nadir will have a better outcome under a combination 
of PLEX and intravenous methylprednisolone, than intravenous corticoids 
alone.66 
1.2.5.4 Intravenous immunoglobulins  
Intravenous immunoglobulins have been widely used in neurological 
disorders as they are involved in the blocking of membranolytic attack 
complex, idiotypic antibodies or exert Fc region-mediated inhibition of 
antibody production, saturating Fc receptors and the suppression of 
inflammatory molecules such as metalloproteinasas and chemokines.67 
There are no clinical trials concerning the use of intravenous 
immunoglobulins in ATM and most of the data come from MS or NMO trials. 
Considering MS, there are controversial results among randomized trials,68,69 
although it seems that intravenous immunoglobulins do not exert a beneficial 
effect in relapsing-remitting MS, as a multicentre double blind, placebo 
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controlled  trial has showed.70 No randomized placebo control studies have 
been performed in NMO patients although prospective studies and case 
series suggest a beneficial role in treating acute NMO relapses.71,72  
1.2.5.5 Chronic complications and management 
In the acute phase, physicians must carry out several stabilizing measures in 
order to avoid further acute or chronic complications. Mandatory approaches 
are respiratory or oropharingeal support derived from the bulbar damage. 
Rehabilitation is also important in order to improve tonic spasticity or motor 
weakness, as well as the placement of catheterism due to the urine retention 
or other symptoms derived from autonomic dysfunction such as constipation 
or bowel incontinence. Moreover, it is well known that neuropathic pain 
could be an initial uncomfortable symptom that deserves prior attention.73 
In clinical practice, these interventions are based on observational studies 
coming from other neurological diseases. (Symptomatic treatment for ATM 
complications are shown in Appendix 1) 
 
1.2.6 Prognosis 
1.2.6.1 Functional outcome  
Long term outcome varies widely from asymptomatic to wheel chair 
dependent or even death in a few proportions of patients. Classical studies 
reported that one third of patients had mild residual sequeale, one third had 
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a moderate degree of disability and lastly, one-third of patients were wheel 
chair dependent at the end of the follow-up.10,13,39 In recent years, studies 
performed after the TMCWG criteria have shown similar prognostic rates. 
The proportion of IATM patients with poor outcome (inability to walk) has 
been observed up to 35,8%.34-37,40 
Recovery usually begins within one to three months after the onset of 
symptoms and improvement can be observed up to two years.74 
Fatal outcome has been classically reported in patients suffering from 
myelitis.1 Death rates within the first year of the disease have decreased over 
the last decades from 14,7% to 4,8%.10,40 Risk of death is most frequently a 
result from hospitalization itself and bed resting; namely pulmonary 
embolism or aspirative bronchopneumonia.39 Less frequently, respiratory 
failure due to bulbar affection is reported in the acute phase.40 The highest 
death rate has been related to myelopathies which are secondary to spinal 
cord infarction. However, deaths in this subgroup of patients have been 
reported after a long follow-up and are likely related to elderly and vascular 
risk factors than being directly related to the myelopathy.75 
1.2.6.2 Prognostic factors associated with recovery  
Clinical prognostic factors have been largely proposed in patients who 
present a first episode of ATM. Spinal shock, back pain, motor involvement, 
rapid progression of symptoms, relapse occurrence and severe functional 
deficit at nadir of symptoms have all been related to poor prognosis in older 
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studies.10,11,13,39,43 Nonetheless, spinal shock and a higher Rankin score at the 
onset of symptoms have been the only independent factors related to poor 
outcome in patients who strictly fulfill the TMCWG criteria for IATM.34,37 
Regarding MRI factors, an extensive spinal cord lesion over more than two 
vertebral segments has been related to a worse functional outcome both in 
classical and recent studies.16,35,36,39 
Other studies have shown that neurophysiological findings could be 
implicated in ATM prognosis. Absence of motor or somatosensory evoked 
potentials and denervation in lower limbs muscles were proposed as the 
main variables indicating a worse outcome.16,39,76 
Finally, molecular biomarkers suggesting a worse recovery after a first 
episode of ATM have also been described. CSF 14-3-3 protein was reported 
as a surrogate biomarker of short term to clinically defined MS conversion in 
patients with an initial demyelinating episode, including ATM.77 Moreover, 
CSF 14-3-3 predicted little recovery and a higher disability at the end of the 
follow-up.77,78 Others have failed to confirm the usefulness of the CSF 14-3-3 
in both ATM and MS.79 CSF Cistatyn C, a protease inhibitor of glial and 
neuronal cells, has been correlated to neurological disability in ATM patients 
who presented with at least one relapse of the disease.43 Authors have 
suggested that CSF Cistatyn C might be an unfavorable prognostic factor of 
ATM. The same group did not replicate the findings regarding prognosis in a 
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further study although CSF Cistatyn C levels were significantly increased in 
IATM compared to CIS and non inflammatory disorders.80 
 
1.2.7 Recurrent acute transverse myelitis 
It is well known that recurrent ATM is related to demyelinating CNS 
conditions such as MS, NMO, ADEM or autoimmune systemic disorders.18,81 
Nonetheless, there are a proportion of ATM patients without an underlying 
cause who still develop further episodes of spinal cord inflammation. 
Relapsing forms of IATM were early reported on, suggesting a separate 
condition from ACTM or APTM.17,82,83 Further on, some authors stated that 
idiopathic relapsing ATM forms underline differential findings from other 
CNS demyelinating disorders such ATM associated with MS (ATM-MS). Male 
predominance, absence of OCB in CSF and a higher number of relapses than 
ATM-MS were proposed to be distinctive features of idiopathic relapsing 
ATM.84 
Serum AQP4-ab is a major risk of recurrence after an episode of ATM,85,86 and 
most of the studies mentioned above were reported before this antibody was 
described. Therefore, idiopathic relapsing ATM patients could belong to 
NMOSD, as Chan KH, et al. suggested.81 In the first study validating the 
current TMCWG criteria, de Seze J, et al. reported that up to 24% of patients 
fulfilling the TMCWG criteria for IATM followed a relapsing course (94,4% of 
them presented LETM on spinal cord MRI). However, the AQP4-ab test was 
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lacking in this study.34 A subsequent study also carried out under the TMCWG 
criteria disclosed that 20 out of 29 patients (69%) diagnosed with IATM had 
a relapsing form. In this study, patients underwent the AQP4-ab test and six 
resulted in being positive.35 A recent study analyzing 192 patients who 
initially presented with IATM under the current criteria revealed a 57% of 
recurrences after excluding AQP4-ab positive patients.87 
Regarding relapsing risk factors, previous studies have identified some 
markers of recurrence. AQP4-ab is considered a consistent biomarker not 
only for recurrence but also for the diagnosis of NMOSD.26,85 Moreover, 
relapsing ATM and, more specifically APTM, could be the beginning of a 
subsequent MS. OCB, abnormal IgG index in CSF and  brain lesions on MRI at 
initial event of spinal cord inflammation are predisposing factors to develop 
MS and, therefore, a relapsing myelitis in this context.88,89 A longer lesion 
extension at the first spinal cord MRI has been reported as an independent 
predictor for relapse in patients presenting with LETM.90 
Serum biomarkers such as lower 25-hydroxivitamin D levels and the 
presence of anti-Ro (SSA) autoantibodies have also been significantly 
associated with recurrent spinal cord inflammation compared to the 
monophasic form.91,92 Both biomarkers as well as OCB and an abnormal IgG 
index in CSF have been further confirmed as being risk factors for recurrent 
ATM in a recent study evaluating initial AQP4-ab seronegative IATM. In this 
study, authors described other variables associated with recurrence. Among 
demographic and clinical variables, African-American, female gender and 
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those presenting with LETM had a significant higher risk of myelitis 
recurrence. Regarding laboratory variables; pleocytosis and high titers 
(≥1:160) of antinuclear antibodies (ANAs) were also found to be related to 
recurrence.92 
 
1.3 Acute transverse myelitis in demyelinating disorders 
1.3.1 Multiple Sclerosis 
1.3.1.1 Clinically isolated syndrome  
MS is the most common chronic disabling disease of CNS in young adults in 
Western countries. This disorder is characterized by multifocal CNS 
demyelination whose diagnosis relies on objective dissemination in time and 
space.93 In more than 85% of patients who later develop MS, clinical onset 
appears with an acute or subacute episode of neurological disturbance due to 
a single white-matter lesion. This presentation is known as CIS and usually 
consists of optic neuritis (ON), brainstem involvement or partial myelitis.94 
Patients who present with CIS are at a high risk of MS conversion. MRI and 
CSF findings have been shown to be the most valuable markers of MS 
conversion after CIS. Those patients with an initial abnormal brain MRI have 
a higher risk of conversion to MS than those with a normal brain MRI.95 
Moreover, the presence of OCB in CSF increases two-fold, the risk of having a 
second demyelinating attack.96 
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1.3.1.2 Clinical and paraclinical features  
Myelitis represents up to 21% of CIS (spinal cord-CIS) and APTM is the major 
spinal expression of spinal cord lesions in MS.97 Clinically, MS patients who 
develop an initial spinal cord demyelinating episode will present with clinical 
asymmetrical distribution.17 Sensory disturbances are the most frequent 
symptoms described followed by motor weakness. Sphincter dysfunction is 
less frequent among spinal cord CIS patients.17,89,98 
The presence of OCB in CSF has been described in the majority of spinal cord- 
CIS patients (57-92%).17,88,89,99 One study described CSF inflammatory 
features (abnormal IgG index or OCB) in 74,8% of these patients.98 
In one recent multicenter study, at least one brain MRI lesion was observed 
in up to 87% of patients who presented with spinal cord- CIS. This study and 
others have reported that up to 60% of these patients fulfilled the Barkhof 
criteria at first brain MRI.89,99 
Spinal cord lesions in MS patients are characterized by a well– circumscribed 
focal T2 hyperintensity involving one to two contiguous vertebral segments 
(Figure 5). Spinal cord location in MS patients typically affects the cervical 
level (80%) the thoracic segment being less frequently involved (20%).100 In 
the axial plane MS patients often present with lateral or posterolateral 
lesions. Moreover, MS lesions usually extend to less than one-half of the 
cross-sectional cord area.101 Another distinctive radiological finding in MS 
patients is the trophy of the spinal cord, although this feature is usually 
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observed in progressive forms of MS and more rarely seen as a part of 
relapsing forms.101 Moreover, at the time of the myelitis, some studies have 
shown that MS patients have more than one spinal cord lesion.75,102 
 
Figure 5. Spinal demyelinating lesion in Multiple Sclerosis patient. 
   
 
The conversion rate to MS after a first spinal cord demyelinating episode 
range between 43,8% and 92% in different studies.17,88,89,98,99 The 
development of MS dramatically decreases to 15-45% if only ATM patients 
without brain lesions are evaluated.28,88,99 Lastly, when the TMCWG 2002 
criteria for IATM are applied, the conversion rate is even lower (0-11%).32,34-
37 
1.3.1.3 Prognostic factors of long term outcome  
Cobo Calvo, Álvaro                              Acute non compressive myelopathies 2015 
 
57 
 
Some predictive factors for MS conversion from spinal cord- CIS have been 
identified. Among the demographic factors, family MS history, younger onset 
and female gender have been described.37,88,98 Clinical features at onset of 
symptoms such as higher disability or sensory symptoms have also been 
reported.88,99 Among CSF factors, the presence of OCB, abnormal IgG index or 
high cell count indicate a higher predisposition towards conversion to MS. 
Finally and considering MRI data, abnormal brain MRI and posterolateral 
location of lesions at first spinal cord MRI are described as predictive factors 
for conversion to MS  in patients with a spinal cord CIS.15,88,89,98,99,103 
Taken together, inflammatory CSF findings and brain lesions on MRI allow us 
to foresee MS conversion. One recent study evaluating MS conversion after a 
first event of APTM described conversion rates from 1,4% to 50% after a 
mean follow-up period of 8,7 years,  when combining the presence of OCB  in 
CSF and at least one brain lesion (Figure 6).89 
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Figure 6. Flow Chart of patients presenting with an initial acute transverse 
partial myelitis. (From Bourre B, et al.)89 
 
 
Some studies have tried to find some variables associated with a poor term 
outcome in patients with a first spinal cord- CIS. One study found that a 
higher number of spinal cord lesions was related to higher disability.99 
However, another recent study was unable to identify any clinical, biological 
or MRI factors at onset of symptoms as predictive factors of long-term 
disability in spinal cord-CIS patients.89 
 
1.3.2 Neuromyelitis optica spectrum disorders 
1.3.2.1 Historical and evolving concepts in Neuromyelitis optica  
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NMO was originally described by Eugène Devic as a monophasic syndrome 
consisting of acute severe spinal cord inflammation and bilateral 
simultaneous or sequential ON in close temporal succession (1858-1930).104 
Eugene Devic and Fernand Gault reported another 17 patients with similar 
features soon thereafter.105 Since then, a dilemma concerning the 
classification of NMO arose and NMO was regarded either as an MS subtype 
or as a separate entity. Several case reports came to light during the last 
century reporting patients with monophasic or a relapsing type of myelitis 
and simultaneous or subsequent ON.106,107 NMO was classically recognized to 
evolve as a relapsing disorder that also included patients with unilateral ON 
and those with episodes of ON and myelitis occurring weeks or even years 
apart. The relapsing forms were related to a more severe disability than its 
monophasic counterparts. Regarding CSF findings, pleocytosis and the 
absence of OCB were frequently observed in NMO. In MRI studies, myelitis 
usually extends over three or more vertebral segments with diffuse 
abnormalities involving the cervical and thoracic spinal cord. Brain MRI was 
commonly reported as normal or nonspecific.108,109 
A putative marker for NMO was described by the Mayo Clinic group in 2004. 
AQP4-ab were observed in patients with NMO diseases or at a higher risk of 
developing this disease such as monophasic LETM or recurrent LETM or ON. 
AQP4-ab reacts with the AQP4 channel at the astrocytic end-feet, the main 
channel regulating the water homeostasis in the CNS. The sensibility and 
specificity of this autoimmune maker was reported to be 73% and 91%, 
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respectively.26 Building on this discovery, the same group proposed the 
current criteria for NMO (Figure 7).25 
 
Figure 7. Neuromyelitis optica criteria. (From Wingerchuk DM ,et al.)25 
 
 
Shortly thereafter, the clinical spectrum of NMO was proposed as follows: 
Idiopathic single or recurrent events of LETM, recurrent or simultaneous 
bilateral optic neuritis, optic neuritis of LETM associated with systemic 
autoimmune disease or myelitis associated with brain lesions typical of NMO. 
They also included the Asian optic-spinal form of MS.110 
Substantial evidence, not only the discovery of AQP4-Ab but also clinical, 
laboratory and immunopathological data suggested that NMO disease is a 
distinctive entity from MS.111,112 Although most of the classical features of 
NMO remain unchanged, subsequent extensive clinical experience revealed 
that MRI abnormalities may appear in up to 60% of NMOSD patients. New 
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findings may herald the onset of NMOSD and warrants particular emphasis 
such as hypothalamic disorders (narcolepsy and inappropriate antidiuretic 
hormone syndrome) and brainstem symptoms (intractable hiccup and 
nausea or vomiting).113-117 (Figure 8) 
 
Figure 8. Brain MRI findings in Neuromyelitis optic patients 
 
 
A not depreciable proportion of patients who fulfill Wingerchuck criteria for 
NMO do not present serum AQP4-Ab despite the refinement of the 
methods.118 Moreover, one study reported different epidemiological, clinical 
and radiological features in AQP4-Ab seronegative NMOSD from those who 
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were seropositive. In seronegative NMO patients both genders were equally 
affected, Caucasians were the predominant ethnic group, concurrent ON and 
LETM at onset was more frequently observed and they developed a better 
visual acuity recovery compared to their seropositive counterparts.119 
1.3.2.2 Myelitis as a first event of Neuromyelitis optica spectrum disorders 
1.3.2.2.a Epidemiology and positivity for AQP4-ab 
Myelitis, together with ON is a cardinal symptom in NMOSD. Although in the 
vast majority of cases the length of myelitis extends over three or more 
contiguous segments, at least 7,3% of patients could present with shorter 
lesions.120 Among NMO patients, isolated LETM appears up to 45,6% as the 
initial manifestation and up to 17,6% of patients might  present together with 
ON.121 (Figure 9) 
Figure 9. Longitudinal extensive transverse myelitis in NMO patient. A) T2-
weighted hyperintensity, B) T1–weighted hypointensity, C) Centromedular 
NMO lesion 
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Divergent results have been obtained regarding the frequency of AQP4-ab 
seropositivity in LETM patients. Meanwhile some authors have reported 
AQP4-ab seropositivity up to 89%,85,122-126 others have observed lower 
frequencies.90,102,127,128 The causes of such discrepancies are still unclear 
although the most likely are selection bias (first-ever LETM vs LETM with 
history of ON or myelitis and collaborative multicentre studies vs hospital-
based series), inclusion of different ethnic groups and  different methods of 
AQP4-ab detection.  
1.3.2.2.b Extensive myelitis with and without aquaporin- 4 antibodies 
(Appendix 2) 
Different epidemiological data have been reported between those patients 
who present with a first AQP4-ab seronegative LETM and those who are 
seropositive; male predominance seems to be related to seronegative 
patients in most of the studies.122,124,125,127 Moreover, contradictory results 
have been described regarding age of presentation; while some studies have 
described a younger age of presentation in AQP4-ab seronegative patients,125 
others have described an older onset.124 Regarding clinical findings, 
brainstem symptoms such as nausea and vomiting or paroxismal tonic spasm 
were associated with the seropositive form.115,125 These patients might also 
present with a more severe onset of symptoms.124,128 Although a lower 
relapse rate is clearly related to AQP4-ab seronegative LETM, a better 
recovery at the end of follow-up has only been reported in one study.123 
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Among studies, other differences between both groups have been described 
with less consistent results. In relation to laboratory features, less proportion 
of abnormal IgG index and pleocytosis have been related to AQP4-ab 
seronegative LETM,123,124 as well as less  coexistence of autoimmune 
antibodies.124,125 Considering MRI features, AQP4-ab seropositive patients 
have been found to show more white matter lesions on brain MRI.122,124 After 
excluding myelin oligodendrocyte glycoprotein (MOG) antibody (MOG-ab) 
seropositive LETM, a recent study observed that AQP4-ab seropositive 
patients had more contiguous vertebral segments affected than 
seronegatives.124 Moreover, this and another study observed that 
hypointense lesions on T1- weightened spinal cord MRI were related to the 
seropositive group.122,124 Location of the spinal cord lesion may be another 
distinctive feature between groups. Central grey matter involvement has 
been related to AQP4-ab seropositive patients and a spinal cord involvement 
at a lower level (conus medullaris) to seronegatives.122,123,125 Other 
paraclinical data such as visual evoked potentials have shown a delay latency 
in AQP4-ab seropositive patients compared to seronegatives.128 
1.3.2.3 Conversion rate to Neuromyelitis optica after a first extensive  
myelitis 
Patients who present with a first episode of LETM are at a high risk of 
recurrence and  NMOSD conversion.25 In a prospective study, 21,7% of 
patients who present with a first episode of LETM developed NMOSD.85 Other 
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studies focused on LETM have reported between 20% and 60% of converters 
to NMOSD.122,123,127 Importantly, AQP4-ab is a predictive marker of 
recurrence and therefore, a marker to NMO conversion. Although NMO 
conversion is higher in AQP4-ab seropositive LETM patients (up to 
83%),85,122,123 AQP4-ab seronegative LETM may also convert to NMO or 
develop recurrences in up to 25%.85,122,123 (Figure 10) 
 
Figure 10. Survival analysis comparison of the risk of developing NMO 
between AQP-4 and AQP-4negative LETM. (From Chang HK, et al.)123 
AQP4-ab positive (n=18) vs negative (n=12), p=0,001 
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1.3.2.4 Treatment 
Long-term treatment in limited forms of NMOSD remains unclear. A panel of 
experts has set up a scheme depending on the clinical course and the AQP4-
ab serostatus. Hence, patients presenting with AQP4-ab seropositive LETM 
will need immunosuppressant due to the high risk of NMO conversion. 
However, it is not the case in AQP4-ab seronegative LETM where we should 
individualize the treatment. The panel do not recommend beginning with 
immunosuppressive agents unless the attack is severe or the recovery is 
poor.129 
The overall rationale of NMO therapy is to decrease disability by improving 
acute events. Following this aim, several immunosupressants have been used 
in order to prevent or minimize further attacks of NMO. 
The panel recommends Azathioprine as a first line therapy.129 This purine 
synthesis inhibitor which interferes with lymphocyte proliferation, was 
analyzed in a retrospective study showing a reduction in the annual relapse 
rate over a median treatment of 22 months.130 Azathioprine takes up to three 
months to exert its beneficial effect and an initial combination with oral 
prednisolone may be useful. One prospective study showed a sustained 
Expanded Disability Status Scale (EDSS) improvement and absence of 
relapses by combining Azathioprine and this corticoid.131 Recommended 
doses of Azathioprine are 2,5-3 mg/kg/day and with prednisone being 
gradually reduced, should be considered after two or three months. A further 
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first line therapy is Rituximab.129 Rituximab is a chimaeric anti-CD20 
monoclonal antibody whose main function is to deplete naive and memory B 
cells. Multiple surrogate doses and time intervals have been used. The two 
most recommended options are four weekly doses of 375mg/m2 or a 1000 
mg infusion with a 2 week interval between the infusions followed by re-
infusions after 6-12 months. However, in some studies Rituximab was 
administered depending on the circulating B-cell number. This treatment has 
shown to be very useful in NMO by reducing both the annualized relapse rate 
and the EDSS.132,133 
As a second line therapy the panel recommends Cyclophosphamide (7-25 
mg/kg every month over a period of 6 months), Mitoxantrone (12 mg/m2 
every three months for nine months) and Mycophenolate mofetil (1/3 g day). 
In addition to their use as an acute therapy, oral corticosteroids and plasma 
exchange may be used as a chronic treatment. Finally, intravenous 
immunoglobulins may be used as an additional treatment.129 
1.3.2.5 Functional outcome  
Functional outcome in patients with LETM largely depends on the final 
diagnosis.125,127 Before the AQP4-ab description, de Seze J, et al. observed that 
94% of patients diagnosed with IATM under the TMCWG criteria had an 
extensive lesion on MRI. This study reported that 35,5% of the whole cohort 
were unable to walk at the end of the follow-up.34 After the discovery of 
AQP4-ab, few studies have focused on LETM prognosis. Although AQP4-ab 
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have been related to a higher risk of relapse, most of the studies did not show 
differences regarding disability between AQP4-ab seropositive and 
seronegative LETM.124,125 Only one study reported a worse outcome in AQP4-
ab seropositive LETM patients compared to  seronegatives.123 
Inability to walk independently was observed in 35% and 6% of patients 
among AQP4-ab seropositive and seronegative LETM, respectively.125 
Another recent study involving 23 LETM patients (only two patients tested 
positive for AQP4-ab) disclosed that 13% remained wheelchair dependent 
meanwhile more than half  recovered with minimal disability.90 
Although there is not much data regarding mortality in LETM patients, one 
study whose aim was to distinguish clinical and paraclinical features between 
AQP4-ab positive and negative LETM patients, reported that 5 (all of them 
were AQP4-ab positive) out of 76 patients died after a median follow- up of 
five years.125 
1.3.2.6 Prognostic factors associated with recovery 
Only one prospective study has focused on clinical factors associated with 
prognosis in LETM patients, so far. In this study, EDSS at nadir was predictive 
of the final functional outcome.90 Another study also reported that EDSS at 
nadir was associated with a worse clinical outcome in most of the patients 
(94%) including those presenting with LETM.34 
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1.3.3 Acute demyelinating encephalomyelitis 
1.3.3.1 Concept and current criteria  
ADEM is a symptomatic diffuse or multifocal CNS inflammation typically 
observed in paediatric patients.134 
ADEM is commonly preceded by a non-specific infection or febrile state in up 
to 74% of patients. In most of the cases, a precedent respiratory infection has 
been described. Moreover, ADEM can also develop after several different 
vaccines, namely measles, mumps or rubella vaccination. Latency between 
prodromal infectious symptoms or vaccine administration and ADEM onset 
may vary from any time between 14 days and three months.135 On the basis 
of the above data, some authors suggest that molecular mimicry may be 
responsible for the acute demyelination observed in ADEM.136 
ADEM patients presented with a polysymptomatic picture at onset of 
symptoms; headache and fever, ataxia, altered mental state or brainstem 
symptoms such as opthalmoplejia, dysartria or dysphagia are the most 
frequent ones observed.134,137 However, other clinical symptoms may be 
observed such as ON or motor weakness (13 and 23% of patients, 
respectively).137 The clinical course of ADEM is acute and symptoms peak 
over few days.135 In Table 1, current ADEM criteria are shown.138 
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Table 1. International Pediatric Multiple Sclerosis Study Group criteria for 
ADEM.  
 
Multiphasic ADEM 
 A new event of ADEM three months or more after the initial episode 
that can be associated with new or re-emergence of prior clinical and 
MRI findings. Timing in relation to steroids is no longer pertinent 
 
 
   Monophasic ADEM 
 A first  polyfocal, clinical CNS event with presumed inflammatory 
demyelinating cause 
 Encephalopathy that cannot be explained by fever 
 No new clinical and MRI findings emerge three months or more 
after the onset 
 Brain MRI is abnormal during the acute (three-month) phase. 
 Typical of brain MRI: 
- Diffuse, poorly demarcated, large (>1–2 cm) lesions 
involving predominantly the cerebral white matter 
- T1 hypointense lesions in the white matter are rare 
- Deep grey matter lesions (e.g. thalamus or basal ganglia) 
can be present 
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Although there are some controversies about the possibility of recurrences in 
ADEM, there is a proportion of patients who will present further relapses 
(between 25-33%).139,140 These patients will be considered as having 
multiphasic ADEM if the two episodes are separated by three months but no 
followed by further episodes. Moreover, if no alteration of consciousness is 
observed, MS or NMO will be considered as the probable cause.  
1.3.3.2 Paraclinical features 
Radiological features of ADEM are non specific although brain MRI usually 
shows both hemispheres asymmetrically affected by multifocal, widespread 
and extensive white matter lesions. In one study, thalamus, basal ganglia and 
brainstem lesions were often present (32,4% and 42%, respectively).137 
Although less frequently observed, spinal cord lesions are present in up to 
28% of patients.134 The length of the spinal cord lesion length is usually more 
extensive in ADEM patients than in IATM. One study reported that up to 92% 
of ADEM patients had extensive lesions on spinal MRI and 29% of them had 
gadolinium enhancing lesions.141 (Figure 11) 
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Figure 11. Radiological lesions in ADEM patients 
 
 
CSF findings reveal evidence of inflammation with pleocytosis or raised 
proteins in most of the cases. OCB and abnormal IgG index in CSF are usually 
absent.134,135 
ADEM prognosis remains quite variable due to the differences in patient 
inclusion among different studies. If most of the studies are considered 
together, two thirds of patients have a complete recovery.142 One recent 
study of 33 paediatric ADEM patients reported that 90,1% presented a 
recovery with minor neurological signs after a mean  follow-up of 9,2 
years.140 
 
1.4 Acute transverse myelitis in connective disorders  
1.4.1 Sjogren's syndrome  
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Sjogren's Syndrome (SS) is an autoimmune disorder characterized by 
mononuclear infiltration and predominantly the destruction of the lachrymal 
and salivary glands leading to xerostomia and xerophthalmia. However, this 
disorder may involve other visceral organs such as CNS. Pathology in SS 
could be produced by the disease itself or secondary to other connective 
diseases such as systemic lupus erythematosus (SLE) or arthritis.143 
Neurological complications have been observed between 20-25% of SS 
cases.144 Moreover, in the largest retrospective study performed to date 
reporting 82 SS patients with neurological symptoms, 56% of them had CNS 
involvement ranging from symptomatic white matter lesion on brain MRI to 
focal or multifocal neurological symptoms such as ON or transverse myelitis. 
In this study, myelitis was diagnosed in 35,4% of patients and for 61% of 
these patients the spinal cord involvement was the first SS manifestation.144 
Clinically, myelitis in SS is often severe with sphincter dysfunction and para 
or tetraparesis.144 Regarding radiological features, LETM has been observed 
in up to one third of cases. Cervical region was the most commonly affected 
(82% of myelitis patients) and half of them showed a centromedular location 
in the axial plane.144 In contrast with these results, one South-Korean study 
described a higher frequency of extensive lesions with a mean length of 7,6 
vertebral segments on MRI. In this study, all but one SS patients with myelitis 
also had NMO.145 
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1.4.2 Systemic lupus erythematosus and antiphospholipid syndrome 
SLE is a multisystem autoimmune disorder of the connective tissue which 
involves CNS in 56% of patients.146 Neurological deficits range from 
headache and visual alterations to seizures, psychosis and stroke. Myelitis is 
estimated to affect 1-2% of patients with SLE.147 ATM often appears within 
five years from the diagnosis of SLE but may be the initial manifestation in up 
to half of them.148 Typically, the spinal lesions extends to more than three 
contiguous vertebral segments.149 
In one of the largest retrospective studies focussing on SLE with myelitis, 
sensory deficit was the most frequent initial symptom, followed by motor 
deficit and urinary sphincter dysfunction. Herein, almost 20% of patients 
presented with recurrences during the follow-up. Regarding the MRI 
findings, LETM was most frequently localized in the cervical and mid-lower 
thoracic spinal segments.149 
Two different patterns of myelitis affection in SLE patients has been recently 
described;150 a grey matter syndrome characterized by rapid and severe 
onset with poor recovery and a white matter syndrome with a mild 
paraparesis and better recovery. The former was mainly monophasic and 
AQP4-ab were present in 12,5% patients meanwhile the latter was relapsing  
with AQP4-ab in 57% of the cases. 
Few studies have focused on prognostic factors in SLE with myelitis. One 
recent report described that one third of patients presenting with SLE and 
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myelitis had unfavorable outcome after six months of follow-up. The initial 
severity of symptoms was the main prognostic marker of the outcome.151  
Antiphospholipid antibodies are target proteins that interact with 
phospholipids present in the plasma membrane of cells whose function is the 
blood clotting cascade regulation. Thus, antiphospholopid antibodies and in 
particular lupus anticoagulant, anticardiolipin and anti Beta-2 glicoprotein-1 
antibodies could be potential direct contributors to CNS lesions. Some 
authors have suggested that these antibodies might play a critical role in 
ATM pathogenesis due to vascular injury secondary to vasculitis and 
hypercoagulablitiy.152 Although ATM due to antiphospholopid syndrome is 
rare, one study observed that 73% of SLE patients who presented with 
myelitis, tested positive for antiphospholopid antibodies.153 
 
1.4.3 Behçet's disease 
Behcet's disease (BD) is a multisystemic chronic, relapsing inflammatory 
disorder of unknown etiology which may affect CNS, besides the 
mucocutaneous and ocular involvement. Although the prevalence of 
neurological affection in BD depends on geographical distribution, it has 
reported to be between 2-44%.154 The most commonly affected CNS areas in 
BD are brainstem and basal ganglia whereas the spinal cord is less often 
involved. One recent study reported spinal cord lesions in 11% of BD 
patients.154 Spinal lesions in BD are characteristically multifocal and may 
enhance gadolinium.155 Some patients may develop extensive spinal lesions 
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which may even extend to the whole spinal cord.156 The functional outcome 
in BD patients presenting with myelitis can lead to a bad prognosis and is 
even worse compared to those who present with involvement in other CNS 
regions.155 
 
1.4.4 Sarcoidosis 
Sarcoidosis is a multisystemic granulomatous disease of unknown aetiology 
affecting mainly the respiratory system. Sarcoidosis may be the cause of CNS 
affection in approximately 5% of cases. However, spinal cord involvement in 
Sarcoidosis is rarely observed. It may appear in the form of arachnoiditis, 
extradural or intradural lesions, and intramedullary involvement.157 
In one of the largest retrospective series published on spinal cord 
involvement among Sarcoidosis patients, most of the lesions observed were 
extensive with a mean length of six vertebral contiguous segments. Lesions 
were heterogeneous with central distribution in the axial plane. During the 
follow-up, one third presented with relapses, one third remained monophasic 
and one third had a progressive course. In this study, most of patients 
presented sequelaes at the end of the follow-up.158 
 
1.4.5 Neuromyelitis optica and connective diseases overlapping 
NMOSD and connective disorders such as SLE or SS have been proposed to be 
overlapping disorders. Some authors have suggested that AQP4-ab might be 
the underlying pathogenesis of these autoimmune diseases. Moreover, the 
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fact that AQP4-ab positive NMO patients have a higher frequency of non- 
organ specific autoantibodies than seronegatives, supports the notion of an 
underlying autoimmune predisposition in the former group.159 
AQP4-ab mediated NMOSD with AQP4-ab have also been related to other 
diseases such as Myasthenia Gravis or myopathy.160,161 
 
1.5 Infectious diseases and postvacunal acute transverse myelitis 
Infectious and parainfectious diseases may trigger demyelinating spinal cord 
lesions. Among them, the herpes virus family (virus herpes simplex, varizela 
herpes virus and Citomegalovirus) and VIH virus are the most commonly 
involved. Bacterial (Treponema pallidum, Mycobarcterium tuberculosis and 
Borrelia burgdorferi) or parasites such as Schistosomiasis are more rarely 
observed. Fever, meningismus, rash, an immunocompromised state or 
recurrent genital infections may suggest an specific aetiology.162 (Figure 12) 
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Figure 12. Infectious agents involved in myelitis. (From Jacob A, et al.)38  
 
 
 
Vaccines have been related to an immunological reaction leading to myelitis. 
Smallpox, rabies, hepatitis B, typhoid or influenza have been implicated, 
among others.38 
Finally, the term parainfectious NMO has been proposed for patients with 
viral or bacterial pathogens who fulfill NMO criteria. In one study attempting 
to characterize parainfectious NMO, varizella zoster virus and Mycobacterium 
pneumoniae were the most frequently observed agents.163 
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1.6 Other causes of acute transverse myelitis 
Spinal infarctions may be a rare cause of spinal cord affection. Patients 
usually develop symptoms and reach nadir within minutes or within a few 
hours. Blockage or disruption of the anterior spinal cord lead to infarction of 
the anterior two thirds of the spinal cord.164 Arteriovenous shunts or spinal 
arteriovenous fistulaes may also lead to spinal cord lesions spanning more 
than three vertebral segments.165 Another cause of spinal cord infarction 
although less often observed is fibrocartilogenous embolisms which have 
been reported in up to 5%.166 Prognosis in patients with spinal cord 
infarction is often poor with permanent and disabling sequelae.167 CSF 
findings are characterized by proteinorraquia with an absence of pleocytosis 
and OCB.29 
Although intramedullary tumours (ependymomas, astrocytomas, most 
commonly observed) or metastasis are the cause of a chronic myelopathy, 
some of them might be responsible for an acute onset and mimic the 
symptoms of myelitis.168 
Paraneoplastic syndromes could be responsible for subacute myelopathies. 
Among the paraneoplastic antiibodies, collapsine response- mediator protein 
5 (CRMP-5/CV-2) which has been also related to ON, seem to be the most 
frequent antibody related to myelopathies. Small cell lung cancer is the main 
underlying tumour associated with this antibody.169 Amphiphysin antibodies 
have also been found in patients with myelopathy.170 Other paraneoplastic 
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antibodies such as glutamic acid decarboxylase (GAD), antineuronal nuclear 
antibodies (ANNA-2), Purkinje cell antibodies have also  been involved in 
myelopathies.38,171 
Vitamin-B 12 deficiency is the cause of a predominantly subacute sensory 
myelopathy due to latero-dorsal affection of the spinal cord. Subacute 
combined degeneration due to vitamin- B 12 deficiency is usually observed in 
the context of chronic gastritis with the absence of intrinsic factor.172 
Acquired copper deficiency is a non-compressive myelopathy, clinically 
characterized by posterior column dysfunction which closely mimics 
subacute sensory myelopathy. The main causes are gastric surgery, zinc 
consumption or malabsortion.173 
 
1.7 Myelin oligodendrocyte glycoprotein (MOG) antibody and myelitis 
1.7.1 MOG protein and demyelinating disorders 
MOG is a quantitatively minor type I transmembrane component of the 
myelin, comprising of 0,05% of the whole structure. Its IgV-like domain, 
located in the outer surface of myelin lamellae, seems to exert 
encephalitogenic properties.174 (Figure 13) Both experimental allergic 
encephalomyelitis and “in vitro” studies have shown enhanced demyelination 
after MOG immunization.175,176 Although the pathological relevance of MOG 
has been tried to be demonstrated in different studies, its potential role in the 
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process of the disease is still unknown. Meanwhile “in vitro” studies have 
remarked that only the antibodies against conformational MOG epitopes are 
pathogenic leading to demyelination and axonal damage,177 others have 
suggested a pathologic effect via complement activation.178  
 
Figure 13. Myelin oligodendrocyte glycoprotein location on the myelin 
sheath 
 
 
MOG-ab have been increasingly recognized in pediatric patients with 
demyelinating conditions. Up to 57,6% and 14% of pediatric patients 
diagnosed with ADEM and MS were shown to have serum MOG-ab, 
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respectively.178-185 High titers of MOG-ab have also been found  in a lower 
proportion of pediatric patients reporting NMO or relapsing ON.178,186,187 
Most of the data regarding serum kinetic of MOG-ab in demyelinating 
diseases comes from pediatric populations. It seems that MOG-ab kinetic 
depends on the underlying condition. They are present in serum after the 
initial episode and titers continuously decline over a period of time in 
pediatric patients with ADEM disease.184,185 Some authors have associated 
the persistence of high titer MOG-ab in serum with poor recovery or relapses 
in ADEM pediatric patients.182,185 Other chronic diseases such as MS or NMO 
seem to have a different kinetic profile and MOG-ab remain stable over 
time.182,184,186 Few data are available regarding only adult patients. A recent 
study reported that only two among 14 MOG-ab positive patients diagnosed 
with NMOSD became seronegative after a median follow-up of 23 months. 
MOG-ab titers in these patients were related neither to prognosis nor to 
relapses.188 
Association between MOG-ab and AQP4-ab in NMO patients has been rarely 
described. One pediatric and three adult NMO patients have been reported 
with double seropositivity for both antibodies.178,188 
 
1.7.2 MOG antibodies and Neuromyelitis optica spectrum disorders 
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Considering NMOSD in adult populations, MOG-ab have been detected in up 
to 9,8%.188,189 (Table 2) 
Table 2. Different phenotypes according to MOG serostatus in NMOSD 
  Sato DK, et al.189 Höfterberg R, et al.188 *Kitley J, et al.190 
MOG-ab positive/NMOSD, n (%) 16/215 (7.4)          17/174 (9.8) 9/29 (30) 
NMO, n (%) 1/16 (6,3) 4/17(24) 4/9 (44) 
NMOSD- LETM, n (%) 5/16 (31.2) 5/17 (29) 3/9 (33) 
NMOSD-ON, n (%) 10/16 (62.5) 7/17 (41) 0/9 
n, number; MOG-ab, myelin oligodendrocyte glycoprotein; NMO, Neuromyelitis optica; 
NMOSD, Neuromyelitis optica spectrum disorders; LETM, longitudinally extensive transverse 
myelitis; ON, optic neuritis 
*Comparison between AQP4-ab positive and MOG-ab positive NMOSD 
 
Different epidemiological, clinical and radiological features have been 
described between AQP4-ab and MOG-ab positive patients with NMOSD. The 
median age of onset of symptoms has been reported to range between 32 and 
37,5 years in MOG-ab positive NMOSD patients compared with older range of 
ages in those with AQP4-ab.188,190 In other data such differences were not 
found.189 Moreover, a male predominance has also been observed ranging 
from 53% to 62,5% in MOG-ab positive NMOSD patients.188-190 
MOG-ab have been associated with NMO patients with simultaneous ON and 
myelitis attacks at onset (classical Devic's Neuromyelitis optica) compared to 
those who have AQP4-ab.189,190 However, other authors have reported no 
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differences between AQP4-ab and MOG-ab positive in patients who fulfilled 
Wingerchuck criteria for NMO regarding this clinical presentation.188 Among 
NMOSD, MOG-ab are related to monophasic forms of the disease compared to 
those patients who report AQP4-ab. Up to 50% of these MOG-ab positive 
patients will not develop further relapses after a median follow-up of two 
years.189 Among patients with recurrences, MOG-ab positive NMOSD patients 
seem to have a lower number of relapses than AQP4-ab and seronegative 
patients.189 Moreover, MOG-ab positive NMOSD patients seem to have a 
better recovery compared to those with AQP4-ab or without either of 
them.188,189 
Regarding the location of spinal cord lesion at onset of symptoms, some 
groups have suggested a predominance in the lower levels of the spinal cord 
(lumbar and conus medullaris) in the MOG-ab group compared with the 
AQP4-ab group.189,190 Kitley J, et al. have also suggested that a transient 
abnormal spinal cord lesion on MRI could be another feature of MOG-ab 
positive NMOSD.190 Moreover, antinuclear antibodies are reported in a higher 
proportion in MOG-ab positive patients.189 
 
1.7.3 MOG antibodies in different clinical phenotypes of Neuromyelitis optica 
spectrum disorders 
There are not many studies which detail distinctive clinical features of MOG-
ab positive patients according to the clinical phenotype.187-189,191 
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1.7.3.1 Neuromyelitis optica and MOG antibodies 
MOG-ab have been found in up to 8,7% of patients fulfilling Wingerchuck 
criteria for definite NMO.178,188,189 MOG-ab positive NMO patients tend to be 
younger, to have a higher male: female ratio and higher pleocytosis than 
AQP4-ab patients. Moreover, they seem to have a better outcome.188  
1.7.3.2 Optic neuritis and MOG  
The frequency of MOG-ab in ON patients without AQP4-ab has been found to 
be 46% and 18% in children and adults, respectively.187,188 Patients with 
MOG-ab who develop ON seem to have a good follow-up visual 
acuity.188,189,191 A recent study has reported better visual acuity and visual 
field deficits at long term in this subgroup of patients than in AQP4-ab 
seronegative ON patients. In most of patients tested by optic computer 
tomography, authors also pointed out that their retinal nerve fiber layer 
thickness returned towards a normal range.191 Moreover, MOG-ab positive 
patients will be more likely to develop a higher frequency of ON relapses than 
negatives.  It has been recently observed that 38 out of 40 ON recurrences 
among a cohort of NMOSD patients belonged to the MOG-ab positive 
group.188 In this study, bilateral ON attacks were more common in MOG-ab 
positive patients than in those seronegative both for AQP4 and MOG-ab.188 
Lastly and regarding treatment, MOG-ab positive patients with ON seem to 
have a  faster recovery after steroid initiation. Nonetheless, they will be more 
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likely to relapse on steroid cessation, compared to MOG-ab negative 
patients.191 
1.7.3.3 MOG and longitudinal extensive transverse myelitis  
It has been described that between 6% to 7,5% of AQP4-ab seronegative 
patients who present with an isolated LETM had serum MOG-ab.125,188,189 
Höftberger R, et al. compared both subgroups of LETM patients.188 MOG-ab 
positive patients presenting with an isolated episode of LETM appeared to 
have clinical distinctive findings than those who are seropositive for AQP4-ab 
or seronegative for both MOG and AQP4-ab. Compared to AQP4-ab positive 
LETM patients, MOG-ab positive were younger and presented with a 
monophasic form. However these differences were not observed between 
MOG-ab positive with AQP4-ab seronegative LETM patients. Patients 
presenting with MOG-ab positive isolated LETM were characterized by better 
prognosis than seronegatives. Moreover, the lesion extended over the whole 
spinal cord in a higher proportion of the MOG-ab positive group and a 
significant resolution or reduction of the lesion imaging was observed during 
the follow-up in comparison to the AQP4-ab positive group.188 
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2. HYPOTHESIS AND OBJECTIVES 
2.1 Hypothesis 
1. IATM patients who fulfill the TMCWG criteria established in 2002 would 
present distinctive epidemiological, clinical, laboratory and radiological 
features at the acute phase of the disease which might lead to identify those 
with a worse functional long term outcome. 
2. TMCWG criteria reliability to dismiss ATM as the initial event of a 
subsequent MS remains unclear in daily clinical practice. There might be a 
proportion of IATM patients who convert to MS, even though fulfilling the 
TMCWG criteria. 
3. The functional outcome in LETM patients is highly variable depending on 
the aetiology. Patients presenting with a first episode of LETM might present 
initial distinctive epidemiological, clinical, laboratory and radiological 
features related to the functional long term outcome. 
4. Although LETM is a characteristic clinical feature of NMO and part of the 
diagnostic criteria of the disease, LETM may encompass a heterogeneous 
group of disorders. The relative frequency of the different aetiologies causing 
a first LETM episode is not well known. We think that the idiopathic form is 
overrepresented and that unacknowledged underlying pathogenesis might 
be related to the demyelinating episode in this subgroup of these patients.  
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5. The underlying aetiology of a proportion of patients with a first event of 
AQP4-ab seronegative LETM remains unclear after a long workup and follow-
up. MOG-ab might be present in the serum of these patients.  
6. Patients with AQP4-ab seronegative LETM who have MOG-ab in serum 
might have epidemiological, clinical, laboratory and radiological features 
different from those who are MOG-ab seronegative. 
 
2. 2 . Objectives 
1. To analyze the functional long term outcome and prognostic factors 
associated with recovery in patients who fulfill the TMCWG criteria. 
2. To describe the MS conversion rate and identify variables associated with 
MS conversion in patients who fulfill the TMCWG criteria for possible and 
definite IATM.  
3. To describe the outcome, and to identify predictors of outcome in patients 
presenting with a first episode of LETM. 
4. To describe the aetiologic spectrum of patients presenting with a first 
episode of LETM. 
5. To investigate the frequency of MOG-ab in patients with a first episode of 
AQP4-ab  seronegative LETM.  
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6. To describe the clinical features of patients with a first episode of AQP4-ab 
seronegative LETM who are seropositive and seronegative for MOG-ab in 
serum. 
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3. MATERIALS AND METHODS 
3.1 Methodology 
The present work is subdivided into three studies: 
1. Idiopathic acute transverse myelitis 
2. Longitudinal extensive transverse myelitis 
3. Myelin oligodendricyte glycoprotein antibodies in longitudinally extensive 
transverse myelitis 
 
In the first study, we included patients who fulfilled the definition for definite 
or possible IATM proposed by the TMCGW 2002 criteria.19 We conducted a 
retrospective medical chart review from patients admitted to Internal 
Medicine, Neurosurgery and Neurological departments at Bellvitge 
University Hospital between January 1989 and December 2011. 
Although the presence of AQP4-ab are not included in the TMCGW 2002 
criteria, we excluded those patients who were positive for this antibody, as it 
has been shown to be a direct pathogenic cause of NMOSD.26 
We noted epidemiological and clinical data as well as disability at onset and 
last visit based on the modified Rankin Scale (mRS) for IATM patients and the 
EDSS for patients who converted to MS. We categorized patients into mRS <2 
or ≥ 2 to differentiate better and worse functional term outcome. CSF 
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characteristics were also analyzed. Baseline brain and spinal cord MRI were 
performed on a 1.5 Tesla system in all patients. 
All patients were followed-up at 6 months intervals during the first year and 
once a year thereafter. MS diagnosis was based on the revised Poser or 
McDonald criteria.93,192 
For the statistical analysis, we used Chi-square test and Mann-Whitney U test 
for categorical variables and Student t Test for continuous variables. 
Pearson’s correlation coefficient performed correlations between ordinal 
variables. We performed a multivariate logistic regression in order to analyze 
predictive factors. Statistical analyses were performed by SPSS version 20.0. 
 
In the second study, we reviewed medical histories from patients who 
presented with a first LETM episode at Bellvitge University Hospital (Internal 
Medicine, Neurosurgery and Neurological departments) between January 
1993 and January 2011. 
The inclusion criteria for LETM were: 1, onset of symptoms over no more 
than 21 days; 2, spinal cord T2 signal hyperintensity over three or more 
consecutive vertebral segments; 3, bilateral motor or sensory symptoms with 
or without sphincter dysfunction; 4, available brain MRI. The exclusion 
criteria were: 1, previous spinal irradiation; 2, evidence of spinal cord 
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compression; 3, history of neurological disease or symptoms; 4, no symptoms 
or signs attributable to involvement other than the spine. 
Epidemiological and clinical data were noted. Disability was evaluated by 
mRS and patients were categorized into two groups, mRS<2 or ≥ 2 with the 
higher score indicating clinically significant functional disability. 
CSF and MRI details were evaluated, as described in study 1. An extensive 
workup was performed in order to rule out infectious agents, connective, 
autoimmune, vascular or malignant disorders causative of LETM. AQP4-ab 
were no systematically sought as the technique was available at our centre in 
2007.193 
We defined eight aetiologies: 1, MS based on Poser or McDonald criteria;93,192 
2, ADEM;194 3, NMOSD;25,110 4, parainfectious myelopathy;75 5, SLE;195 6, 
SS;143 vascular aetiology differentiated in spinal cord infarction and dural 
fistula,18; 7, tumour related;196 and 8, idiopathic LETM if the presence of 
LETM with no other cause is identified after an extensive workup and follow-
up. 
Statistical analysis was only performed in four subgroups (MS, PIM, systemic 
diseases and idiopathic LETM), as the patient number was too low in the rest 
of subgroups. Mann Whitney U test or Chi square test were used for 
quantitative variables or categorical variables, respectively. Univariate 
analysis followed by stepwise multivariate logistic regression was performed 
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to assess factors associated with functional outcome. SPSS version 20.0 
program was used for the analysis. 
 
For the third study, patients diagnosed with isolated AQP4-ab seronegative 
LETM from Lyon and Toulouse University Hospitals and Bellvitge University 
Hospital were included. We performed a retrospective analysis from data 
which were entered in a prospective way between January 2005 and 
December 2014 into the Database adapted from the EDMUS system (Eugène 
Devic European Network, EDEN).197 
Inclusion criteria for isolated AQP4-ab seronegative LETM were: 1, onset of 
symptoms between 4 hours and 21 days; 2, bilateral or sensory symptoms 
with or without sphincter dysfunction; 3, spinal cord T2 signal hyperintensity 
over three or more consecutive vertebral segments on MRI; 4, available brain 
MRI; 5, extensive workup that reasonably excludes other diagnoses such as 
vascular, compressive, infectious, metabolic, paraneoplasic or radiation 
myelopathy; 6, tested for AQP4- ab in serum with a negative result. 
Demographic and clinical data were collected. Disability was evaluated on 
admission and on the last visit based on the EDSS. Patients were categorized 
into two groups: EDSS ≤ 2,5 and EDSS ≥ 3 for functional outcome. 
CSF and MRI data were also collected. AQP4-ab and MOG-ab were analyzed in 
two centres, the Lyon Neuroscience Research Centre of Lyon and the 
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Laboratory of the Neurommunolgy Programme, Institut d’Investigació 
Biommèdica August Pi i Sunyer (IDIBAPS) of Barcelona, by cell-based assays, 
as previously reported.119,188,198 
All patients were followed-up every 6 months and when a relapse was 
suspected. MS and NMO diagnosis were based on revised McDonald criteria 
and Wingerchuk 2006 criteria, respectively.25,93 
Categorical and continuous variables were compared with Fisher exact test 
and Mann- Whitney U test, respectively. The analysis of prognostic factors 
was carried out by multivariate logistic regression model. Cox regression 
analysis was performed to estimate cumulative survival probabilities. All 
statistical analyses were performed using STATA (64-bits) software. 
 
3. 2 Ethical aspects 
All the studies had the approval from the Clinical Research Ethic Committees 
of Bellvitge University Hospital, Lyon and Toulouse University Hospitals, and 
all data were collected in an anonymous fashion.  
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4 RESULTS 
4.1 Study 1. IDIOPATHIC ACUTE TRANSVERSE MYELITIS: OUTCOME AND 
CONVERSION TO MULTIPLE SCLEROSIS IN A LARGE SERIES. 
Cobo- Calvo A, Mañé Martínez MA, Alentorn-Palau A, Bruna Escuer J, 
Romero Pinel L, Martínez- Yélamos S. BMC Neurology 2013, 13:135 
In the first study, we included 85 patients who fulfilled the TMCWG 2002 
criteria for IATM. 
Demographic and general clinical features  
We observed that IATM patients fulfilling the TMCWG 2002 criteria were 
represented by a slight increase in the female:male ratio (1:0,9) with a mean 
(Standard deviation, [SD]) age of presentation of 43 (16,2) years. After a 
median (interquartile range [IQR]) follow-up of 2,9 (1-4,8) years, 11 (13%) 
patients converted to MS and 74 (87%) remained as IATM. 
Considering clinical aspects, the onset of IATM symptoms were preceded by 
back pain in up to 40% and 31,8% had previous symptoms related to 
infection. Moreover, urinary and anal sphincter dysfunction were presented 
in 55,3% and 13% of IATM patients at onset, respectively.  
LETM was observed in 26 (30,6%) of patients; two (7,5%) patients were 
diagnosed as having MS and 24 (93,1%) remain as IATM. Those patients who 
presented spinal cord relapses were observed in the MS group and none of 
them presented an initial LETM. 
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On follow-up completion, 37% had moderate disability (mRS ≥ 2) and 9,4% 
were unable to walk unassisted. Moreover, 27% of patients with LETM were 
wheelchair dependent as compared to only 1,7% of patients without an 
extensive lesion on spinal MRI. 
Variables associated to MS conversion 
Onset of symptoms at an early stage was related to MS conversion. Patients 
from the MS group developed IATM symptoms at a mean (SD) of 28,2 (9,1) 
years compared to 45 (16) years in the IATM group.  
CSF findings proved to be of high value when added to IATM prognosis. We 
found that 33,3% of IATM patients presenting with OCB in CSF had MS 
conversion compared to only 2% without OCB. This finding was significantly 
related to MS conversion, but lost strength after multiple comparison 
adjustement. Moreover, a negative OCB testing and IgG index ≤ 0,7 
combination was proven to be useful to identify those IATM patients who will 
not develop MS conversion, as the negative predictive value was 100%. 
Predictive factors associated with outcome 
A higher mRS was related to a poorer outcome in univariate analysis 
(p<0,001). However, urinary sphincter dysfunction and LETM at baseline 
MRI were the only two independent risk factors associated with a worse 
functional outcome (mRS ≥ 2) in patients who presented with an episode of 
IATM fulfilling the TMCWG 2002 criteria. 
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Study 2. ETIOLOGIC SPECTRUM AND PROGNOSIS OF LONGITUDINALLY 
EXTENSIVE TRANSVERSE MYELOPATHIES.  
Cobo- Calvo A, Alentorn A, Mañé Martínez MA, Bau L, Matas E, Bruna J, 
Romero Pinel L, Martínez- Yélamos S. Eur Neurol 2014; 72 :86-94. 
In this study we included 72 patients who fulfilled the criteria for the very 
first acute LETM. 
Final diagnosis classification at follow-up completion 
After a median (IQR) follow up of 34 (17,2-63) months, the most frequent 
diagnosis was the idiopathic form of LETM (30,5%) followed by MS (25%). A 
parainfectious aetiology was identified in 14,9% of patients; 4 viral, six 
bacterial and one patient due to Mycobacterium tuberculosis. SLE and SS were 
observed in 12,2% of patients. The other aetiologies identified, were spinal 
cord infarction and NMOSD in each of three patients and ADEM, dural fistula 
and tumour-related LETM in each of two patients. 
Demographic and clinical relevant features  
Among the whole cohort, LETM was diagnosed at a median (IQR) age of 41,5 
(29-61,5) years and 45 (62,5%) patients were women. The median (IQR) 
length of contiguous vertebral segments in patients with a first episode of 
LETM was 5 (3-6,75). 
MS patients were characterized by an onset of symptoms at an early age, a 
milder initial mRS score at onset and a lower frequency of sphincter 
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dysfunction compared to the rest of the aetiologies. Moreover, the presence 
of OCB and a cervical location on spinal cord MRI were related to MS patients. 
In our population, we observed that only a small proportion of patients (5%) 
tested positive for AQP4-ab. The two patients who were positive for AQP4-ab 
were diagnosed with NMOSD at completion of follow-up. 
Mortality is relatively frequent in LETM patients and 9,7% of them died at the 
end of the follow-up. Mortality was mainly observed in the vascular group. A 
high proportion of LETM patients had moderate disability and 72,2% of 
patients had an mRS ≥ 2. Idiophatic and systemic LETM were the most 
disabling aetiologies. 
Predictive factors associated with outcome 
Although sphincter dysfunction was related to poor outcome in the 
univariate analysis, the only two variables associated with unfavorable 
outcome in patients with a first episode of LETM after multivariate analysis 
were mRS ≥2 at admission and older age at onset. 
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Study 3. ANTIBODIES TO MOG IN AQP4 ANTIBODIES  SERONEGATIVE 
LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS: CLINICAL AND 
PROGNOSTIC IMPLICATIONS.  
Cobo-Calvo A, Sepúlveda M, Bernard-Valnet R, Ruiz A, Brassat D, 
Martínez- Yélamos S, Saiz A, Marignier R. Mult Scler 2015. (Accepted, in 
press) 
In the present study, we included 56 patients who met the diagnosis for 
AQP4-ab seronegative LETM.  
Comparison between MOG-ab positive and negative patients 
We observed that 13 (23%) of patients diagnosed with AQP4-ab seronegative 
LETM had MOG-ab present in serum. 
Clinically, MOG-ab positive patients were  characterized by an earlier onset of 
symptoms, higher predisposition to ON relapses, higher ON relapse rate and 
a better functional outcome than MOG-ab negatives. 
Although there were no differences in length, lesion distribution or 
gadolinium enhancement at the spinal cord MRI, we identified 36,4% of 
MOG-ab positive patients who showed a complete resolution of the spinal 
cord lesion on MRI at the last follow-up, as compared to 6,9% of MOG-ab 
negatives. 
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One interesting finding was the relation between MOG-ab patients and the 
presence of CSF pleocytosis (92,3 % in MOG-ab positive group vs 45,2% in 
MOG-ab negative group). 
Predictive factors associated with outcome 
We identified two independent prognostic factors in AQP4-ab seronegative 
LETM patients. A higher disability at onset was related to a worse recovery 
and the presence of MOG-ab with a good outcome. Moreover, we observed 
that MOG-ab positive patients were at a higher risk to present an ON episode, 
and therefore, a higher chances of  conversion to NMO, at the end of the 
follow-up. 
Final diagnosis classification on completion of follow-up  
The diagnostic distribution between MOG-ab positive and negative patients 
was different. Within the MOG-ab positive group, 30,8% of patients had NMO 
conversion, 15,4% presented LETM recurrences and 58,9% remained as 
monophasic LETM, after a median (IQR) follow-up of 43,8 (41,4-68,3) 
months. Only 4,7% of patients converted to NMO, 16,3% had recurrent 
LETM, 76,7% were monophasic LETM and 1,8% had MS conversion within 
the MOG-ab negative group after a median (IQR) follow-up of 38,4 (23,5-
80,1) months. 
MOG-ab  temporal dynamics  
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In five out of 13 MOG-ab positive patients, the serum sample to analyze MOG-
ab was collected in the acute phase (<30 days from onset) and during 
remission in the remainder after a median of 15 months (7-136) from onset. 
During the follow-up, we obtained serum from six patients after a median of 
34 (range, 4-60) months. All but one patient (monophasic LETM) remained 
positive. The sample of the negative patient was collected after 43 months. 
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Abstract 
Objective: We aimed to investigate the frequency and clinical significance of 
antibodies to MOG (MOG-ab) in patients who presented with a first episode 
of seronegative AQP4 antibodies (AQP4-ab) longitudinally extensive 
transverse myelitis (LETM). 
Methods: Epidemiological, clinical, and paraclinical data of 56 patients from 
three European centers were analyzed. Patients were retrospectively tested 
for MOG-ab and AQP4-ab, by cell-based assays. 
Findings: Thirteen (23.2%) patients were MOG-ab positive. Among the 56 
patients, 6 (10.7%) converted to neuromyelitis optica (NMO), 1 (1.8%) to MS, 
9 (16.1%) had recurrent LETM, and 40 (71.4%) remained as monophasic 
LETM. Compared with seronegative patients, those with MOG-ab were 
younger (median: 32.5 vs 44 years; p=0.007), had more frequently 
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cerebrospinal fluid pleocytosis (94% vs 45%, p=0.003) and had better 
outcome (median EDSS 2.0 vs 3.0, p=0.027). MOG-ab positive patients also 
showed an increase risk of optic neuritis relapse and NMO conversion 
(p=0.010).  
Conclusion: Patients with MOG-ab in AQP4-ab seronegative LETM have 
clinical distinctive features, higher risk of optic neuritis relapses, and better 
outcome than patients seronegative. 
 
INTRODUCTION 
Longitudinal extensive transverse myelitis (LETM) refers to an inflammation 
of the spinal cord extending at least three vertebral segments in length at 
spinal cord imaging.1 Although LETM is a characteristic clinical feature of 
neuromyelitis optica (NMO) and part of the diagnostic criteria of the disease,1 
LETM at presentation may also be the prelude of a wide range of 
autoimmune or infectious diseases, and ischemic or metabolic disorders as 
well.2 
Antibodies to aquaporin-4 (AQP4-ab) are the most valuable prognostic factor 
of recurrence or conversion to NMO after a first episode of isolated LETM.3 
However, up to 50% of patients presenting with isolated LETM remain 
seronegative for AQP4-ab, despite the refinement of detection methods,4-6 
and some of them will convert to NMO.7  AQP4-ab seronegative LETM differs 
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from seropositive ones in several demographic and clinical features,4 but 
whether AQP4-ab seronegative LETM represents a homogenous entity 
remains unclear. Hence, a first episode of AQP4-ab seronegative LETM is still 
a challenge in daily clinical practice and there is a need to identify further 
markers to predict the clinical course of this condition. 
Humoral immune responses to native myelin oligodendrocyte glycoprotein 
(MOG), a  transmembrane component of the outer surface of myelin lamellae 
with encephalitogenic properties,8 have been detected specifically in patients 
with inflammatory central nervous system (CNS) demyelinating diseases 
using cell based assays.9 These MOG-ab have been mainly described in 
paediatric patients with acute demyelinating encephalomyelitis (ADEM).10,11 
Interestingly, they have also been found in children and adults patients with 
NMO and suspected limited forms of the disease who are AQP4-ab 
seronegative.12-16 
The aim of the present study was to investigate the frequency and clinical 
significance of MOG-ab after a first episode of AQP4-ab seronegative LETM. 
 
METHODS 
Patients 
Fifty-six patients with a first episode of isolated LETM seronegative for 
AQP4-ab (inclusion criteria in Table 1) from three European 
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Neuroimmunology Centers (Universitary Hospital of Lyon, and Toulouse, 
France; and Universitary Hospital of Bellvitge, Spain) were included in the 
study. Data were prospectively collected from January 2005 through 
December 2014 and entered into the Database adapted from the EDMUS 
system (Eugène Devic European Network, EDEN)),18 and retrospectively 
analyzed.  
Demographic (gender, age, and ethnicity) and clinical data including 
topography and number of relapses were collected. Patients were followed 
every six months and additionally when relapses were suspected. Relapse 
was defined as a second inflammatory episode at the spinal cord or other 
CNS structure after one month from the first episode and sustained at least 
24 hours in the absence of fever or infection.  
Disability was evaluated on admission and last visit based on the Expanded 
Disability Status Scale (EDSS).19 Multiple sclerosis (MS) and NMO conversion 
were based on McDonald and Wingerchuk 2006 criteria, respectively.1,20 
Date of conversion was noted.  
Description of the number of levels affected on spinal cord magnetic 
resonance imaging (MRI) was determined in T2-weighted sequences in the 
sagittal plane, and brain MRI lesions were classified as normal and abnormal 
with or without Paty’s criteria.21 Follow-up spinal MRI were available in 40 
patients. Results were classified as follows: normal imaging, decrease or 
increase lesion in length and atrophy. 
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Cerebrospinal fluid (CSF) was analyzed for cell count, protein content, IgG 
index and oligoclonal bands (OCB) by using immunofixation electrophoresis 
at the referring hospital for all patients.  
 
Cell-based assays 
Samples were tested for AQP4-ab and MOG-ab in two centers, Lyon 
Neuroscience Research Center of Lyon and laboratory of the 
Neuroimmunology Program, Institut d'Investigació Biomèdica August Pi 
iSunyer (IDIBAPS) of Barcelona, by live cell-based assays and using the same 
protocols and plasmids, as reported.7,15,22 Briefly, for MOG-ab, HEK293 cells 
were transfected with the full- length MOG C-terminally fused to enhanced 
green fluorescence protein (the clone was a gift from Dr. M Reindl). After 24 
hours, HEK293 transfected cells were incubated with patient's serum at 37 
ºC for 30 minutes. They were fixed with 4% PFA for 10 minutes and 
permeabilized with 0.3% Triton X-100, thereafter. Alexa Fluor 594 was used 
as a secondary antibody against human IgG in order to immunolabeled the 
HEK cells. Transfected HEK293 cells were analyzed in Lyon by flow 
cytometry (BD, FACS Canto™; serum dilution 1:620), and in Barcelona by 
indirect immunofluorescence (serum dilution 1:160). All samples were 
investigated by two investigators blinded to the clinical data (R.M in Lyon, 
and A.S. in Barcelona). Previously, coded samples were exchanged between 
both centers and the results showed a complete agreement. 
Cobo Calvo, Álvaro                              Acute non compressive myelopathies 2015 
 
128 
 
Samples used in this study were stored a -80 ºC at Biobank Institut 
d'Investigació Biomèdica de Bellvitge [IDIBELL] and Neurobiotec from 
Hospices Civils de Lyon. The study was approved by the ethics committee of 
the Hospital of Lyon, Toulouse and Hospital de Bellvitge. All patients gave 
their informed consent to participate in the study. 
 
Statistical analysis 
Categorical and continuous variables were compared with nonparametric 
test (Fisher exact and Mann–Whitney U test, respectively). Functional 
outcome was evaluated using the EDSS score at the last visit, and patients 
were categorized in two groups: good outcome for those with an EDSS < 2.5 
and moderate to severe disability for those with an EDSS ≥ 3.0 score. The 
analysis of prognostic factors was done by multivariate logistic regression 
model using the forward and backward stepwise method and including only 
those variables with a p-value < 0.20 in the univariate analysis. Cox 
regression analysis was performed to identify independent variables using 
the statistically significant variables from the bivariate study. Statistical 
significance was set at two-tailed p-value < 0.05. All statistical analyses were 
performed using STATA (64-bits) software. 
 
RESULTS 
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Demographic and general clinical features 
Clinical and demographic data of the series are shown in Table 2 and 3. The 
median age of presentation was 39.9 years (interquartile range [IQR]: 32.3-
58.1); in 3 (5.4%) patients the onset was before 18 years. Patients were 
mainly Caucasian (94.6%), 30 (53.6%) were female with a female:male ratio 
1:0.9 (30/26). The median EDSS score at nadir was 5.0 (IQR: 3.5-7.8). The 
majority of the patients were treated with intravenous methylprednisolone, 
nine patients (16.1%) additionally underwent plasma exchange and five 
(8.9%) intravenous immunoglobulins (Table 2). The findings of brain MRI at 
onset were normal in 38 patients (67.9%) and abnormal with Paty´s criteria 
in nine patients (16.1%) (Table 3). Spinal cord MRI performed at the acute 
phase showed a lesion extending over a median of 6 (range: 3-20) vertebral 
segments. The available CSF studies showed elevated cell count (>5/mm3) in 
31/53 patients (56.4%) and OCB in 7/47 patients (14.9%). Long-term 
immunosuppressive therapy was started in 19 patients (33.9%): 
azathioprine in six, rituximab in five, mycophenolate mofetil in six, 
metotrexate in one patient and beta-interferon in the unique patient who 
converted to MS. At the last follow-up (median 42.2 months; IQR:  25-79.5 
months) the median EDSS score was 2.5 (IQR: 1.5-4.8), 49 patients remained 
as idiopathic isolated LETM (monophasic in 40 [71.4%], and recurrent in 9 
[16.1%]), 6 (10.7%) patients had conversion to NMO and 1 (1.8%) patient 
had conversion to MS (Figure 1). 
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Frequency of MOG-ab detection and clinical course 
Thirteen patients (23%) had MOG-ab. In five patients the serum sample was 
collected at disease onset, and in the other eight during remission after a 
median of 15 months from onset (range, 7-136 months). At the last follow-up, 
nine patients remained as idiopathic LETM (7 monophasic and 2 recurrent 
LETM), four converted to NMO (2 patients developed optic neuritis [ON] 
relapses, one had ON and myelitis, and one ON and brainstem symptoms with 
intractable hiccups and vomiting). Follow-up samples were obtained in six 
patients (46%), after a median follow-up of 34.8 months (range, 4-60). One 
patient with monophasic LETM became negative after 43 months, and 5 
remained positive (three monopashic LETM, one recurrent LETM and one 
NMO). 
 
Comparison between MOG-ab positive and negative patients 
MOG-ab positive patients were younger at onset with a median age of 32.5 
years (range, 6.8-70.7 years) compared to 44.1 years (range, 13.5-82.8 years) 
in the negative group (p=0.006). No differences regarding gender or ethnicity 
were found between both groups. One MOG-ab positive patient had been 
previously diagnosed with myasthenia gravis meanwhile three MOG-ab 
negative patients had the coexistence of other autoimmune diseases; 
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psoriasis, rheumatoid arthritis and autoimmune thyroiditis, respectively 
(p=1.0) (Table 2). Within the MOG-ab positive group, four out of 13 (30.8%) 
patients developed subsequent ON relapses compared to only 2 out of 43 
(4.7%) in the negative group (p=0.022). Similarly, MOG-ab positive patients 
had a higher frequency attacks of ON than those who were negative, 
p=0.008). However, no differences were found in the frequency of 
subsequent myelitis between both groups. At last follow-up, MOG-ab positive 
patients had a lower EDSS score (median 2.0; range, 0-5.5) than seronegative 
patients (median 3.0; range, 0-8.0) (Figure 2; p=0.027). In addition, 6 out of 
43 (14.0%) seronegative patients were confined to a wheelchair but none of 
the MOG-ab positive patients. 
Regarding paraclinical data, both MOG-ab positive and negative groups had 
similar length, lesion distribution and gadolinium enhancement on spinal 
cord MRI. But at the last follow-up, 4 out of 11 (36.4%)  MOG-ab positive 
patients showed a normal spinal cord MRI as compared with 2 out of 29 
(6.9%) negative patients (p=0.039). A higher proportion of MOG-ab positive 
patients had CSF pleocytosis compared to negative patients (92.3% vs 
45.2%) (p=0.003) (Table 3). 
Predictive factors associated with outcome 
In the multivariate analysis after adjusting for age, higher disability at onset 
was the only prognostic factor associated with worse recovery (Odds Ratio 
[OR] 1.71 [95% CI 1.24-2.35]; p=0.001), and presence of MOG-ab with good 
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outcome (OR 0.17 95% CI 0.03-0.84]; p=0.030). In addition, seropositive 
MOG-ab patients showed an increased risk of ON relapse, and, therefore, a 
higher cumulative probability of conversion to NMO (Hazard Ratio 8.99; 95% 
CI 1.60-50.59; p=0.010). 
 
DISCUSSION 
In the present study, we show that MOG-abpositive LETM, as compare to 
AQP4-ab seronegative LETM, encompassed a distinctive and relatively 
frequent subgroup. Clinical features are younger age at onset,higher 
predisposition to ON relapses and better prognosis. 
We found that 23% of patients who presented with a first episode of AQP4-
ab seronegative LETM tested positive for MOG-ab. This higher frequency 
than previously described (6-14.3%)4,15,16 may be explained by discrepancies 
in LETM definition, genetic predisposition and unintentional selection bias. 
Our study was unselected, based on a homogeneous ethnic background and 
following acknowledge definition for LETM. We also performed a large and 
comprehensive workup to rule out alternative diagnoses.  
MOG-ab have been more closely related to pediatric than to adult populations 
with demyelinating diseases.10-12,15,16,23 In line with previous studies, we 
observe that MOG-ab were more frequently in younger AQP4-ab 
seronegative LETM patients. Although we did not find significant gender 
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ratio differences between MOG-ab groups, up to 50% of MOG-ab positive 
patients were male. This finding underlines that female gender is not always 
overrepresented in autoimmune disorders and MOG-ab autoimmune 
phenotype appears in a higher proportion of male patients compared to 
other demyelinating diseases.14-16 
MOG-ab patients seem to have a more benign course than AQP4-ab 
seropositive patients or seronegative forms of NMOSD.14-16 We confirm that 
MOG-ab positive LETM patients were less disabled than negatives at long 
term outcome, despite the similar frequency of severe episode at onset and 
the higher relapse rate during the follow-up. We also observed a complete 
resolution of the spinal cord MRI lesions in a significant proportion of MOG-
ab positive patients as reported in previous studies.11,13-15 This good outcome 
could be related to a more sensitive response to steroids in MOG-ab positive 
patients leading to a more rapid recovery.24 Another explanation might be 
the effect of the MOG-ab itself. Indeed, the intracerebral injection of human 
MOG-ab in mice causes only few and transient myelin changes and alteration 
of axonal proteins expression without leukocyte infiltration, and recover 
within two weeks.25 
In the present study, four MOG-ab positive patients fulfilled the current 
criteria for clinical NMO.1 Some studies have reported that NMOSD patients 
show distinctive clinical findings depending on the underlying biological 
profile (MOG vs AQP4 autoimmune phenotype).14-16 Thus, in our opinion, if 
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NMOSD represent a homogeneous entity deserve to be clarified. Some 
authors have recently reinforced the idea of a different pathogenesis between 
MOG and AQP4-ab reporting a MOG-ab positive NMO patient with high 
myelin basic protein CSF level in the absence of glial fibrillary acidic protein 
during an acute attack.26 The identification of new target autoantigens 
involving inflammatory CNS disorders raises the question of whether the 
proper classification of NMOSD patients should be based on the clinical or the 
biological phenotype.  
Interestingly, we observed that most of the MOG-ab positive patients had CSF 
pleocytosis; this finding has also been described in ADEM patients with MOG-
ab.11 None of our patients, however, had clinical or MRI features of ADEM, but 
this fact along with the high prevalence of a preceding infectious prodrome in 
ADEM patients,11  reinforce the interest to investigate the role of previous 
infection as a potential trigger of the immune response in these patients. 
The retrospective nature of the present study entails methodological 
shortcomings. Some samples were obtained in remission or after treatment 
and one could argue about the existence of false negative results among the 
MOG-ab negative patients. However, this possibility appears to be overcome 
by the differences observed between both groups. 
Taken together, our findings suggest that MOG-ab identify a subgroup of 
seronegative AQP4-ab LETM patients with demographic and clinical 
distinctive features. Their recognition has clinical and prognostic 
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implications and, therefore, testing of MOG-ab should be included in the 
workup of patients who present with LETM. 
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Table 1. AQP4-ab seronegative LETM inclusion criteria  
  
AQP4-ab: aquaporin 4 antibodies 
 
 
 
 
 
 
 
 
 
 
 
1. Onset of symptoms between 4 hours and 21 days 
2. Bilateral motor or sensory symptoms with or without sphincter 
dysfunction  
3. Spinal cord T2 signal hyperintensity over three or more consecutive 
vertebral segments on MRI 
4. Available brain magnetic resonance imaging study 
5. Extensive work-up that reasonably exclude other diagnoses such as 
vascular, compressive, infectious,   metabolic, paraneoplastic or radiation 
myelopathy 17 
6. Tested for AQP4-ab in serum with a negative result 
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Table 2. Comparison of epidemiological and clinical features between 
negative and MOG-ab positive LETM patients. 
 
 
MOG-ab: myelin oligodendrocyte glycoprotein antibodies; LETM: 
longitudinally extensive transverse myelitis; EDSS: Expanded Disability 
Status Scale; ON: optic neuritis; IQR: interquartile range; SD: standar 
desviation; IVMP: intravenous methylprednisolone; PLEX; plasma exchange; 
IVIG: intravenous immunoglobulins 
 
 
 
Patients characteristics n=56 All patients 
n= 56 
 
Negative LETM 
n=43  
 
MOG-ab+ LETM 
n=13  
 
p-value 
Age, median (IQR), y 
39.9 (32.3- 
58.1) 
44.1 (34.5- 
62.1) 
32.5 (22.4-36.2) 0.007 
Female, n (%) 30 (53.6) 23 (53.5) 7 (53.9) 0.617 
Caucasian, n (%) 53(94.6) 40(93) 13 (100) 1.00 
 Other autoimmune diseases, n 
(%) 
4 (7.1) 3 (7) 1 (7.7) 1.00 
EDSS score at nadir, median 
(IQR): 
5.0 (3.5-7.8) 4.5 (3.5-8.0) 5.5 (3.5-7.0) 0.790 
 
     <3.5, n (%) 
     3.5-7, n (%) 
     ≥7.5, n (%) 
 
8 (14.3) 
30 (53.6) 
18 (32.1) 
 
6 (14.0) 
22 (51.2) 
15  (34.9) 
 
2 (15.4) 
8 (61.5) 
3 (23.1) 
0.683 
Acute phase treatment, n (%): 
       IVMP 
       PLEX 
       IVIG 
 
46 (82.1) 
9 (16.1) 
5 (8.9) 
 
34 (79.1) 
7 (16.3) 
2 (4.7) 
 
12 (92.3) 
2 (15.4) 
3 (23.1) 
 
0.420 
1.00 
0.076 
Relapsing course, n (%)       16 (28.6)         10 (23.3)        6 (46.2) 0.160 
    LETM relapse 13 (23.2) 10 (23.3) 3 (23.1) 0.650 
    ON relapse 
    Ratio ON Relapses,    media (SD) 
6  (10.7) 
0.2 (0.6) 
2 (4.7) 
0.07 (0.38) 
4 (30,8) 
0.6 (1.12) 
0.022 
0.008 
    Brainstem relapse 1 (1.8) 0 1 (7.7) 0.232 
Time to first relapse,   
median (IQR), mo 
 
5.2 (2.6-8.5) 
 
5.3 (2.7-11.0) 
 
4.7 (2.6-8.3) 
 
0.560 
Chronic treatment, n (%) 19 (33.9) 13 (30.2) 6 (46.2) 0.320 
Last EDSS, median (IQR) 2.5 (1.5-4.8) 3 (2.0-5.5) 2 (0-2.5) 0.027 
Follow-up, median (IQR), mo 42.2 (25-79.5) 38.4 (23.5-80.1) 43.8 (41.4-68.3) 0.370 
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Table 3.  CSF and MRI findings in negative and MOG-ab positive LETM 
patients. 
 
MOG-ab: myelin oligodendrocyte glycoprotein antibodies; LETM: 
longitudinally extensive transverse myelitis; CSF: cerebrospinal fluid; WBC: 
white blood cells; OCB: positive oligoclonal bands; Gad: gadolinium; SD: 
standar deviation 
 
 
 
 
All patients 
n= 56 
 
Negative 
LETM 
n=43 
 
MOG-ab+ LETM 
n=13 
 
p-value 
CSF: 
> 5 WBC/mm3, n (%) 
Protein (g/L), mean (SD) 
OCB, n (%) 
 
31/53 (56.4) 
0.62 (0.4) 
7/47 (14.9) 
 
19/43 (45.2) 
0.63 (0.5) 
6/35 (17.1) 
 
12/13 (92.3) 
0.63 (0.4) 
1/12 (8.3) 
 
0.003 
0.700 
0.660 
Brain MRI at onset, n (%) 
        Normal 
        No Paty criteria 
        Paty criteria 
 
38 (67.9) 
9 (16.1) 
9 (16.1) 
 
28 (65.1) 
8 (18.6) 
7 (16.3) 
 
10 (76.92) 
1 (7.7) 
2 (15.4) 
 
0.888 
Spinal MRI at onset: 
Length, median (range) 
Gad enhancement, n (%) 
 
6 (3-20) 
28/48 (58.3) 
 
6 (3-20) 
23/36 (63.9) 
 
6 (3-20) 
5/12 (41.7) 
 
0.990 
0.198 
Cord lesion  location, n (%) 
        Cervical 
        Cervical-thoracic 
        Thoracic 
        Thoracic-Lumbar 
        All regions involved 
15 (26.8) 
13 (23.2) 
15 (26.8) 
7 (12.5) 
6 (10.7) 
11 (25.6) 
11 (25.6) 
11 (25.6) 
7 (16.3) 
3 (7.0) 
4 (30.8) 
2 (15.4) 
4 (30.8) 
0 
3 (23.1) 
 
 
 
0.287 
Spinal MRI at follow-up, n (%) 
         Lesion decrease  
         Normal 
         Atrophy  
         No changes 
21/40 (52.5) 
6/40 (15.0) 
3/40 (7.5)  
10/40 (25) 
17/29 (58.6) 
2/29  (6.9) 
2/29 (6.9) 
8/29 (27.6) 
4/11 (36.4) 
4/11 (36.4) 
1/11 (9.1) 
2/11 (18.2) 
0.107 
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Figure 1. Final diagnosis classification in MOG-ab (1.a) positive and (1.b) 
negative patients. 
 
 
Figure 2. Expanded Disability Status Scale Scores at nadir and at last visit. 
(2.a). MOG-ab positive patients (2.b). MOG-ab negative patients. *Red line 
indicates mean EDSS 
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5. DISCUSSION 
5.1 General discussion 
ATM may be the initial episode of a wide range of aetiologies, ranging from 
demyelinating diseases to systemic, vascular, metabolic or malignant 
disorders.38,199 Prognosis may vary among underlying diseases leading to 
different degrees of disability. The lack of awareness about the clinical 
evolution in ATM patients at the time of the first episode make it still a 
challenge in clinical daily practice. Thus, the present work has been focused 
on the description of basal variables as well as on the identification of those 
which may lead us to foresee the clinical evolution and prognosis in ATM 
patients.In 2002, the TMCWG established a diagnostic workup panel in order 
to rule out the different aetiologies responsible for ATM. However, there is 
still a proportion of patients with a first episode of ATM whose underlying 
aetiology remains elusive.19 It is likely that the cause of ATM in these patients 
might be an underlying unknown pathomechanism. Notwithstanding, the 
lack of robust diagnostic tools in order to identify the already known 
diseases, might be another possibility. 
Moreover, ATM may be the prelude to a subsequent MS.17 Hence, the 
identification of ATM patients who will develop MS at the time of the first 
episode is crucial for prognosis and therapeutic aspects. 
On the other hand, an extensive spinal cord MRI lesion may be found in some 
patients presenting with ATM. Although this lesion has been classically 
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related to NMO, LETM is often found in other diseases, mainly systemic and 
autoimmune disorders.200 The spectrum of diseases causing LETM has 
scarcely been studied and deserves further research.  This is the reason why 
one section of the present work has tried to identify those disorders which 
are directly related to an extensive myelitis lesion on MRI. 
Recently, MOG-ab have been found in demyelinating diseases such as NMO or 
limited suspected forms and patients suffering from these disorders have 
shown to have distinctive clinical findings.188-190 MOG-ab, whose 
pathogenicity is still under debate, have been mainly related to monophasic 
forms and a better prognosis compared to positive AQP4-ab NMOSD patients. 
MOG-ab might play a role in some forms of myelitis and more specifically in 
LETM with unknown aetiology, as it has been shown in NMOSD. The present 
work is an observational and retrospective study of patients with different 
subtypes of acute transverse myelitis, mainly IATM and LETM. We have 
searched for valuable clinical and biological markers to know the prognosis 
of patients at the time of the first myelitis episode. The identification of such 
markers will have relevant implications not only for a better comprehensive 
understanding of the disease, but also for a suitable patient counseling and 
treatment. 
 
5.1.1 Idiopathic acute transverse myelitis 
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An acute spinal cord demyelinating attack is a potential disabling syndrome. 
In the present cohort of IATM patients, 37,6% of them had some degree of 
disability measured by the mRS at completion of follow-up (mRS ≥ 2). Studies 
performed under the TMCWG 2002 criteria have reported up to 36% of IATM 
patients having poor outcome.35,40 These studies have used different methods 
to measure disability (mRS vs EDSS) as well as different criteria to define 
poor prognosis. Thus, a direct comparison among studies in terms of 
outcome is not completely feasible. We observed that 9,4% of patients 
remained wheel chair dependent at the end of the follow-up (Figure 14). 
This proportion is lower compared to 33,3% described in the French study 
performed under the TMCWG 2002 criteria.34 One of the major causes of this 
discrepancy could be that the most severe cases are seen in tertiary referral 
centres leading to a selection bias. However, our center is the referral centre 
for our district for patients with any symptom suggestive of myelitis and, 
therefore, the cohort included herein would encompass all degrees of 
severity. 
We searched for those variables leading us to identify patients with a worse 
outcome after a first IATM episode. Although a higher severity at onset was 
related to a worse prognosis in the univariate analysis, this variable was not 
significant in the multivariate analysis. The only independent variables 
associated to poor functional outcome were urinary sphincter dysfunction 
and an extensive lesion cord imaging on MRI. 
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Figure 14. Flow chart reflecting IATM subgroups 
  
 
Only a few studies have focused on indentifying IATM prognostic factors 
under the TMCWG 2002 criteria. In line with our results, a higher disability at 
onset and LETM were the two main factors related to a worse functional 
outcome.34,35,37 
Although the current TMCWG 2002 criteria for IATM diagnosis has tried to 
identify those patients who present with an initial episode of ATM and will 
remain idiopathic, there is a proportion of patients who will develop other 
pathologies during the follow-up, such as MS. In our cohort of 85 IATM 
patients fulfilling the above mentioned criteria, we identified 11 (13%) 
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patients who developed MS at completion of follow-up. Our finding is similar 
to other studies reporting MS conversion rates under the TMCWG 
criteria.32,34-37 Taken together, these results underline that there is still a lack 
of consistent validated criteria  to identify MS patients at the time of the first 
ATM.  
The presence of OCB in CSF and a higher brain MRI lesion load have been 
strongly related to MS conversion after CIS.96,201 According to these studies, 
OCB in CSF had a high predictive value for MS conversion in the present 
study. However, we did not evaluate brain MRI aspects, as an abnormal brain 
MRI was an exclusion criteria for the study. An interesting finding was the 
usefulness of combining OCB and IgG index results for MS prediction. 
Patients without CSF OCB and IgG index ≤ 0,7 will unlikely convert to MS. 
Some studies have reported the usefulness of both markers (OCB and IgG 
index ≥0,7) in MS conversion after spinal cord CIS.88,89,98,99,103 However, none 
of these studies were carried out under the TMCWG 2002 criteria. Moreover, 
we observed that an early- onset of symptoms was associated with MS 
conversion after IATM, as previously described.37,98 Other predictive 
epidemiological factors of MS conversion such as family MS background and 
female gender have been described.88,98 Among the clinical predictive factors, 
a predominance of sensory symptoms and a higher severity at onset have 
been reported.88,99 Finally, other paraclinical data such as spinal MRI lesion 
location or cell count in CSF have been related to MS conversion after spinal 
cord CIS.99 On the basis of our results, IATM patiens who are young and have 
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OCB and abnormal IgG index in CSF will be at high risk of develop MS. Despite 
the lack of standardized protocols of follow-up, it would be reasonable to 
closely monitor these patients with a high risk of MS conversion. LETM may 
be the initial episode of NMO.25 Meanwhile some studies have found low 
rates of NMO conversion after LETM,90,102,127 others have reported higher 
rates, ranging from 45 to 60%.123,125 We performed a retrospective chart 
review of all ATM patients admitted to our hospital from the last 22 years. 
During this period, only two (7%) out of 28 patients presenting with an 
initial isolated idiopathic LETM converted to NMO after a comprehensive 
long follow-up. Therefore, in our health district, NMO disease conversion 
after IATM in form of LETM is a rarely observed entity. We think that 
different technical approaches to measuring AQP4-ab, inclusion of LETM 
criteria and genetic background among different studies are probably the 
main causes of such discrepancies. 
We also observed that all LETM patients remained as monophasic forms 
compared to five patients from the MS group who presented with 
recurrences. Although it is well known that LETM is related to a relapsing 
form of myelitis,92 22 out of 26 idiopathic LETM included in the study tested 
negative for AQP4-ab. Among the four patients whose samples were not 
analyzed for AQP4-ab, two converted to MS and the other two died without 
further relapses observed. As the presence of AQP4-ab is one of the major 
factors of myelitis relapse,85 a negative result may explains the absence of 
relapses. According to our results, we believe that unknown mechanisms 
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could be related to isolated idiopathic LETM. In a proportion of IATM 
patients who initially present with prodromal infectious symptoms, the 
infectious agent is not identified either in serum or in CSF with the current 
techniques. In fact, we noted that almost one third of IATM patients included 
in our study had previous symptoms related to infections. We hypothesize 
that antigens could be directly involved in or inducing a cross- reactive 
immune responses in a process denominated “molecular mimicry”. Others, 
such as new target autoantigens involving demyelinating diseases deserve 
further investigations. 
 
5.1.2 Longitudinal extensive transverse myelitis 
LETM is a rare condition, which might be the first manifestation of a broad 
range of diseases. There are only a few studies reporting the spectrum of 
diseases causing LETM as a whole.122,125 
In the present study, the underlying aetiology was not identified in almost 
one third of patients presenting with a first episode of LETM despite a long 
follow-up and workup. Thus, the term "idiopathic LETM" was applied to 
these patients. Our findings are in agreement with Mediterranean studies 
disclosing frequencies between 40 to 86% of idiopathic LETM among 
patients presenting with a first episode of LETM,90,122 as compared to only 
6,6% in one British study.125 In this latter study, AQP4-ab seropositive LETM 
overcame all forms of LETM reaching a positivity of up to 58% of patients. 
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However, authors included patients with previous CNS attacks. This 
methodological aspect may likely explains the aetiological frequencies (eg, a 
higher rate of NMOSD as they included some patients with previous ON or 
LETM). Moreover, the ethnical background in the British study was 
heterogeneous compared to the present study, as 27% of the population 
were non-Caucasian. The ethnicity background may have led to a higher 
proportion of AQP4-ab positive patients, as it has been described that an 
AQP4-ab negative result is more likely to be found in Caucasian than non-
Caucasian patients  who fulfill NMO criteria.119 
Although LETM is not commonly described in MS patients,27 MS was the 
second cause of LETM in our cohort. The higher prevalence of MS in our 
population in comparison to other pathologies, such as NMO, might be one of 
the explanations for this finding. Our observation is supported by other 
groups describing that up to 30% of Caucasian patients presenting with 
LETM converted to MS.102 The MS subgroup showed classical features; a 
younger onset, the presence of OCB in CSF and a cervical location at baseline 
spinal cord MRI. Moreover, when comparing to the rest of the subgroups, 
there were a lower proportion of sphincter dysfunction and milder disability 
at onset in MS patients. Therefore, some baseline findings may allow us to 
identify those patients who present with LETM and will likely convert to MS. 
We think that these features could be used as “red flags” for MS conversion in 
patients presenting with a first LETM. 
Cobo Calvo, Álvaro                              Acute non compressive myelopathies 2015 
 
153 
 
The subsequent two overrepresented groups were secondary to 
parainfectious (15,3%) and systemic diseases (12,5%). Neither of the two 
groups showed distinctive findings at the onset of LETM. Moreover, when 
testing for AQP4-ab in both groups, a negative result was found. AQP4-ab 
mediated NMOSD have been related both to parainfectious and systemic 
disorders. In the former, the term parainfectious NMO syndrome has been 
proposed, referring to those patients fulfilling NMO criteria in which a 
previous infection may play a pathogenic role.88 In the latter, the presence of 
AQP4-ab has been proposed to be the main cause of the spinal cord 
demyelinating episode despite a secondary vasculopathic or other 
complication of such systemic disorders.159 After a comprehensive workup 
and follow-up, no further relapses were observed in any of the two groups 
and therefore, we could exclude NMOSD as a possible cause. Only 5% of 
LETM patients were diagnosed with NMOSD in our cohort. We have already 
mentioned that the diagnosis of NMOSD in our experience, is rare compared 
to other studies reporting higher percentages.125 One could argue that the 
whole cohort was not tested for AQP4-ab, as the test was only performed in 
56,9% of patients. However, none of the patients developed subsequent 
relapses in the form of ON or transverse myelitis after almost three years of 
follow-up and therefore, they did no convert to NMO. We would like to 
underline that the usefulness of AQP4-ab for NMO diagnosis is not mandatory 
and some authors have reported that a positive result for AQP4-ab is only 
necessary in 10% of cases.121 
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In the present study, among all LETM patients, 72,2% of them had a final mRS 
≥ 2. Although there were not significant differences regarding outcome 
among the four major groups, the parainfectious group interestingly showed 
a trend towards a better functional outcome. Some studies reporting 
functional outcomes in ATM patients (not necessary LETM) have observed 
this trend in those secondary to parainfectious diseases.18,75 ATM in the 
context of NMO or seropositive AQP4-ab and spinal cord infarction seems to 
lead to a poorer outcome compared to myelitis secondary to other diseases 
or seronegative AQP4-ab myelitis.18,75,123 However, due to a low number of 
patients in the remaining groups, we could not perform a statistical analysis.  
LETM may lead to relatively high rates of death and a tenth of the patients 
included in the present study died. Spinal cord infarction has been not only 
characterized as being highly disabling but also may lead to high rates of 
mortality.167 In our population, spinal cord infarction was the first cause of 
LETM death related and two out of three LETM patients secondary to spinal 
cord infarction died. Nonetheless, it is difficult to extract from our study any 
conclusion regarding death due to the retrospective nature, differences in 
follow-up and the small number of patients in each group. 
Interestingly, a higher disability and being elderly at onset were related to 
poor functional outcome at the end of the follow-up. One observational 
French study assessing the long term outcome in ATM patients identified 
both an increasing age and disability at onset to be related to a worse 
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functional outcome.75 Another two studies, one French and one Spanish 
including idiopathic LETM myelitis in the majority of cases also found a 
higher disability at onset, as the only predictive factor of poor outcome.34,90 
Thus, our findings are in agreement with the previously reported data 
although they may not be directly comparable to the two last studies 
previously noted as they only included idiopathic LETM patients. 
 
5.1.3 Myelin oligodendrocyte glycoprotein antibodies in longitudinally 
extensive transverse myelitis 
Serum MOG-ab are very well- recognized in ADEM, especially in pediatric 
patients ranging from 35 to 58%,179,180,182,184,185 and have now been 
described in other CNS autoimmune diseases affecting adult 
populations.178,188-190,202 Two relevant studies (one Spanish and another 
Brazilian and Japanese collaborative study) have focused on the frequency 
and clinical characteristics of MOG-ab in NMOSD. Both studies discovered 
similar frequencies of 7,4% and 9,8%, respectively.188,189 Moreover, one 
recent Japanese study comparing AQP4-ab positive and negative LETM 
patients reported that among those who were AQP4-ab negative, 7,5% had 
MOG-ab.124 A higher frequency of MOG-ab positive patients is observed in our 
study. One possible explanation would be that the biological autoimmune 
profile may differ depending on the ethnical background, as we observe in 
NMOSD with AQP4-ab in NMOSD.119 A lack of consensus in LETM definition 
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could also be another possibility to explain such differences. We performed 
an extensive workup and follow-up under the TMCWG 2002 
recommendations in order to include a homogeneous cohort and to dismiss 
other potential underlying aetiologies.  
Optic nerve inflammation in the absence of any signs of experimental 
autoimmune encephalomyelitis after MOG immunization has been 
successfully reproduced in animal models, suggesting that MOG responses 
may exert a direct role in ON pathogenesis.203 In addition, immunization of 
rats with MOG induces lesions involving the optic nerve and the spinal cord, 
similar to human NMO,204 and MOG-specific T and B cells cooperate to induce 
a NMO-like disease.205 In the clinical setting, MOG-ab have been highly 
related to bilateral or recurrent ON in paediatric and adult patients.187,188,191 
In our study, MOG-ab positive patients were at a greater risk of ON relapse 
and presented higher ON relapse rates than those who were negative. A 
higher expression of MOG protein in the optic nerve than in the spinal cord or 
different blood barrier properties of the optic nerve may be some of the 
explanations for this specific predilection.  
Recent animal model approaches have shown a complete resolution of brain 
damage within two weeks after MOG-ab immunization.206 Compared to 
AQP4-ab treated mice where leukocyte infiltration, loss of astrocyte markers 
and subsequent gliosis were observed, MOG- ab mice had a reversible brain 
edema without inflammation.206 MOG-ab may be involved in cytoskeletal 
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changes instead of brain inflammation and neuronal death.206,207 In line with 
our results where there is a significant proportion of MOG-ab positive 
patients with transient abnormalities on spinal MRI, others have also 
observed the same tendency in MOG-ab diseases, such as recurrent ON, 
ADEM or NMOSD.179,185,188,190 
Prodromal infectious symptoms such as fever, rash or meningismus before 
the onset of ATM are important clue points in suspecting an underlying 
infectious aetiology. Moreover, the presence of pleocytosis in CSF requires 
careful evaluation for infection. Even though a potential infection is 
suspected, the infectious agent cannot be demonstrated in CNS in a 
proportion of patients.19 On the other hand, a previous infection has been 
observed in up to 72% of cases in ADEM patients,135 and recently, pleocytosis 
has been related to ADEM patients with MOG-ab.185 The fact that almost all 
MOG-ab patients showed pleocytosis in our study along with the high 
prevalence of a preceding infectious prodrome in MOG-ab patients with 
demyelinating CNS diseases,185,191 makes us consider a previous infection as 
a potential trigger to be studied further. As with other neurological diseases 
such as Guillain Barré Syndrome, we hypothesize that T cells could be 
activated by molecular mimicry after infection, leading to an immune 
response against MOG. Moreover, the absence of intrathecal OCB synthesis in 
all but one of the MOG-ab positive LETM patients deserves to be highlighted. 
This observation has been previously reported in paediatric MOG-ab positive 
patients,182,207 suggesting that the MOG-ab specific humoral immune process 
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occurs predominantly outside the CNS. Some authors have supported this 
hypothesis by the fact that CSF MOG-ab were only detected in patients with 
high serum MOG-ab titres.182 
The most consistent baseline clinical prognostic marker in patients with a 
first episode of idiopathic LETM is a higher disability at nadir.34,90 We confirm 
previous studies and higher disability was the only clinical marker related to 
a worse long-term outcome. Moreover, when comparing outcome in NMOSD 
patients with and without MOG-ab, studies showed that patients with serum 
MOG-ab have a better clinical outcome. We found that MOG-ab seem to be a 
promising valuable marker of good prognosis in the clinical setting of 
patients suffering from LETM.188-190 These data need to be considered as 
preliminary, and prospective studies with a larger number of patients should 
address this question. 
MOG-ab have identified a subgroup of AQP4-ab seronegative NMOSD patients 
with distinctive clinical features who are currently encompassed under the 
umbrella of NMOSD. These patients not only seem to be different from a 
clinical point of view, but also from a pathological one. Recently, Japanese 
authors described one NMO patient disclosing high CSF levels of myelin basic 
protein at the time of an LETM attack. Nonetheless, CSF glial fibrillary acidic 
protein was not elevated. These findings suggest a myelin injury instead of 
astrocyte damage which is typically observed in AQP4-ab positive NMO 
patients.208 Thus, two different biological phenotypes, "astrocytopathy or 
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AQP4-ab" and "oligodendrocitopathy or MOG-ab" would be part of the same 
clinical NMOSD syndrome. The fact that four MOG-ab positive LETM patients 
in our study were diagnosed as having NMO, leads us to the question of 
whether we should classify patients under a clinical or a biological 
phenotype. This classification may have important clinical and therapeutic 
implications and treatment response might depend on underlying biological 
phenotype. Thus, there are already some authors who suggest to differentiate 
the MOG-ab phenotype from NMOSD.209 (Figure 15) 
 
Figure 15. MOG-ab and AQP4-ab potential phisiopathological role in 
opticospinal inflammation. (From Zambil SS, et al.)209 
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5.2 Limitations 
Our studies might involve diverse uncontrolled factors influencing the results 
due to the retrospective nature. We would like to highlight the most relevant 
shortcomings. 
Firstly, one may wonder if treatment strategies could have played a role in 
disability outcomes. Our study was not designed to evaluate treatment 
responses in the clinical setting and the effect of both acute and chronic 
therapies regarding outcome cannot be ascertained. The role of acute and 
chronic immunotherapy related to outcome will only be answered with 
randomized clinical trials. 
Secondly, when evaluating prognostic factors in patients presenting with the 
whole spectrum of LETM, we have only included the main four subgroups to 
perform statistical analysis due to the low number of patients in the 
remainder. Therefore, outcomes and prognostic factors could change if 
including other aetiologies. However, a higher disability at onset seems to be 
the most reliable clinical prognostic marker, as it has also been observed in 
previous studies.34,90 
The target population of the two first studies should be representative of the 
general population from our region and, therefore, the evaluation of only a 
single referral centre could be a potential limitation. Our hospital is the 
referral centre for demyelinating disorders of the whole health area and, 
theoretically, all patients with potential spinal cord symptoms are evaluated. 
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In order to improve the myelitis spectrum, we searched for myelitis diagnosis 
not only in the neurology department but also in those where a patient with 
myelitis could be admitted. This procedure will invariably decrease the 
selection bias and most of the aetiologies will likely to be represented. In the 
third study, we performed a multicentre study due to the low prevalence of 
MOG-ab seropositivity in AQP4-ab seronegative LETM patients. In this study, 
we included in an unselected manner all patients who met the inclusion and 
exclusion criteria for LETM. 
Regarding laboratory techniques, AQP4-ab test had a relatively low 
sensitivity (50-60%) in the two first studies. It is therefore likely that some 
real AQP4-ab positive patients were included in the idiopathic group. 
However, the absence of recurrences and NMOSD conversion support the 
correct classification of these patients. In the third study Cell Based Assays 
techniques were performed to analyze AQP4-ab and Sensitivity was 
increased to 75% meanwhile specificity remained unchanged at 100%, as it 
has been described.119,198 Although these values may always lead to False 
Negative results, sensitivities are according to the highest sensitive methods 
used to date.118 It is also important to underline that there is a proportion of 
MOG-ab patients whose serum samples were collected after the acute phase. 
The delay in serum collection could imply a loss of MOG-ab seropositivity, as 
some MOG-ab titers decrease through the time.182 
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5.3 New issues raised by the work and final considerations 
In the present work we have tried to identify those IATM patients who are at 
high risk of disability and MS conversion when presenting a first episode of 
ATM. The identification of prognostic factors is essential to select those IATM 
patients who will profit from a more aggressive treatment, such as 
plasmapheresis. Moreover, baseline variables at the time of ATM to identify 
MS converters are needed and could be useful to develop new studies and 
clinical trials. 
IATM patients who present with high severity, urinary dysfunction and LETM 
at onset are at high risk of long term disability and should be closely 
monitored. In the same vein, patients who present with IATM at an early age 
or OCB in CSF should be also closely followed in the outpatients clinics for a 
reasonable time in order to dismiss MS conversion. We have observed with a 
high negative predictive value that IATM patients who show neither 
abnormal IgG index nor OCB bands in CSF will unlikely develop MS. Hence, an 
extensive and indepth workup should be performed with the aim of finding 
out other underlying aetiologies or new unknown aetiological markers. 
On the basis of our results, the current TMCWG 2002 criteria are not entirely 
able to identify patients who present with a first ATM and will remain as 
idiopathic. Some patients may evolve to MS or even NMOSD. Therefore, a new 
panel should be proposed to homogenize this subgroup of patients. Firstly, as 
those patients with negative OCB and IgG index in CSF will be unlikely to 
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convert to MS, one could question whether those patients with a positive 
result in both parameters should be classified under the criteria as IATM. 
However, the IATM criteria would increase in specificity to the detriment of 
sensibility. On the other hand, we think that the inclusion of surrogate 
markers such as AQP4-ab or MOG-ab in a new panel could orientate the 
underlying aetiology. Moreover, glial and neuronal markers have been 
related both to MS conversion and disability after CIS.210,211 We think that 
these markers deserve further study as they might help not only to identify 
those IATM patient who will develop MS patients but also their long term 
disability. 
We underline the relatively high proportion of idiopathic forms and the low 
proportion of NMSD found in our population among patients with a first 
episode of LETM. Even though the AQP4-ab technique sensitivity in the two 
first studies may be a possible explanation for false negatives, patients who 
tested negative for this antibody did not fulfill Wingerchuck 2006 criteria.25 
This is the reason why we think there must be other biological underlying 
mechanisms involved in idiopathic myelitis. 
Following this observation, we aimed to investigate the role of MOG-ab in 
AQP4-ab seronegative LETM. This antibody has been proposed to be involved 
in different demyelinating CNS disorders.188,189 Although the mechanism is 
not completely understood, MOG-ab could play a direct role in demyelination, 
it could reflect a secondary immune reaction, a bystander phenomenon or 
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even reflecting a beneficial effect.212 We believe that a secondary immune 
reaction followed by a previous infection might be one of the most probable 
hypothesis. The high proportion of MOG-ab positive LETM patients with CSF 
pleocytosis in our study altogether with the link between MOG-ab and 
pleocytosis in other diseases which are likely triggered by previous 
infections, would support this notion. We not only identify MOG-ab in one 
fifth of idiopathic LETM patients, but also observe that MOG-ab positive 
patients share several distinctive features. This finding could open the door 
to new studies focussing on the role of MOG-ab in demyelinating disorders 
and also to evaluate whether a previous infection is directly related to the 
appearance of MOG-ab in the serum of patients with demyelinating disorders. 
As we have previously stated, an indepth understanding of this antibody 
could allow us to a better definition of the term IATM. 
As the underlying pathomechanism is likely different, the identification of 
both AQP4-ab and MOG-ab biological phenotypes may be the basis to 
properly classify patients in different subgroups when clinical trials 
considering therapeutic options are performed. This categorization would be 
advantageous in order to detect the true benefit of treatments depending on 
the underlying biological phenotype.An important point to be highlighted is 
that some MOG-ab positive patients fulfilled the Wingerchuck 2006 criteria 
for NMO.25 This observation raises the question of whether a positive MOG-
ab result in patients presenting with ON or myelitis implies a diagnosis of 
NMOSD. We think we should be cautious in applying the term NMOSD in 
Cobo Calvo, Álvaro                              Acute non compressive myelopathies 2015 
 
165 
 
MOG-ab positive patients, and we believe that new refinements of NMO 
diagnostic criteria should be performed. 
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6. CONCLUSIONS 
1. After a median follow-up of 2,9 years, 37,6% of IATM patients had a 
modified Rankin Score ≥ 2 and 9,4% of them were unable to walk unassisted. 
2. Functional long term outcome in IATM was poorer in patients with urinary 
sphincter dysfunction at admission and LETM on spinal cord MRI. 
3. At least 13% of patients who fulfill the TMCWG criteria for definite and 
possible IATM will convert to MS, after a median of three years of follow-up. 
An early-age onset of symptoms was related to MS conversion. 
4. After a median follow-up of 2,7 years, 72% of patients presenting with a 
first episode of LETM had a modified Rankin Score ≥ 2. 
5. An older age and clinically severe disease at onset were independent 
prognostic factors of poorer functional long term outcome in patients with 
LETM. 
6. Whilst the idiopathic form was the most frequent aetiology in patients 
presenting with a first episode of LETM, less than 5% of patients ultimately 
were diagnosed as having NMOSD. 
7. MOG-ab were present in 23% of patients presenting with a first episode of 
AQP4-ab seronegative LETM. 
8. AQP4-ab seronegative LETM patients with serum MOG-ab, as compared to 
those MOG-ab seronegative, encompassed a distinctive subgroup clinically 
Cobo Calvo, Álvaro                              Acute non compressive myelopathies 2015 
 
168 
 
represented by younger age at onset, higher predisposition to ON relapses 
and better long term outcome.  
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8. APPENDIX 
Appendix 1. Symptomatic treatment for Acute Transverse Myelitis 
complications. (From Frohman EM, et al.)50 
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Appendix 2. Longitudinal extensive myeltis with and without aquaporin- 4 antibodies  
2. 1Epidemiological and clinical features of AQP4-ab seropositive and seronegative LETM studies 
2.1.1 AQP4-ab seropositive LETM patients  
 Iorio R, et al.122 Chang K-H, et al.123 Kitley J, et al.125 Sung-Min K, et al.128 Hyun JW, et al.124 Jiao Y, et al.126 
Number of patients 16 18 44 9 55 42 
Female, n (%) 15 (94) 17 (94.4) 38 (86) 6 (66.6) 44 (80) 35 (83.3) 
Age, years, mean (SD) 43 (11-71)* 40.6 (14.8) 45.3 (14.8) 50.3 (12.3) 37.4  (10.1) 50 (15-75)* 
Clinical symptoms at onset, n (%)      
Motor 16 (100) 13 (72.2) 7 (18) n.r n.r n.r 
Sensory 16 (100) 13 (72.2) 13 (34) n.r n.r n.r 
Bladder and bowel 8 (50) 2 (11.1) 0 (0) n.r n.r n.r 
Nausea/Vomits 8 (56) n.r 10 (29) n.r n.r n.r 
Hiccups 1 (6) n.r n.r n.r n.r n.r 
Tonic Spasm 6 (38) n.r n.r n.r n.r n.r 
EDSS at onset, mean (SD) 5.4 (1.8) n.r 7.5 (0-9)** 6.1 (2.1) 8 (2.5-9.5)** n.r 
Final EDSS, mean (SD) n.r 4.3 (22.2) 2 (0-7)** n.r 3 (0-7.5)** 17 (41)**** 
Relapsing patients, n (%) 12 (75) 15 (83.3) 33 (74) 7 (77.8) 48 (87.3) n.r 
Relapse rate, mean (SD) 1.1 (0-3) 0.7 (0.3) n.r n.r n.r 0.8 (0.4-1.8)** 
Time to second attack, 
months, mean (range) 
n.r n.r n.r n.r 4.5 (1-41) 7 (3-34)** 
Follow-up, months mean (SD) 53 (7-146)* 6.1(4.0)*** 61.4 (2.3-260.2)** n.r 7  (4.4)*** 59 (10-318)** 
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2.1.2 AQP4-ab seronegative LETM patients 
 Iorio R, et al.122 Chang K-H,  et al.123 Kitley J, et al.125 Sung-Min K,  et al.128 Hyun JW,  et al.124 Jiao Y, et al.126 
Number of patients 21 12 32 41 42 5 
Female, n (%) 8 (38) 8 (66.6) 14 (44) 9 (22) 9 (21.4) 2 (40) 
Age, y mean (SD)  48.9 (8-78)* 38.4 (14) 37.7 (16.1) 47.2 (12) 43.1 (9.8) 30 (3-52)* 
Clinical symptoms at onset, n (%)      
      Motor 17 (81) 11 (93.7) 5 (16) n.r n.r n.r 
      Sensory 20 (95) 10 (83.3) 10 (32) n.r n.r n.r 
      Bladder and bowel 6 (29) 4 (33.3) 5 (16) n.r n.r n.r 
      Nausea/Vomits 0 n.r 3 (10) n.r n.r n.r 
     Hiccups 0 n.r n.r n.r n.r n.r 
     Tonic Spasm 1 (5) n.r n.r n.r n.r n.r 
EDSS at onset, mean (SD) 5.5 (2.0) n.r 8 (3-8)** 3.2 (1.9) 3 (3-8.5)** n.r 
Final EDSS, mean (SD) n.r 2,67 (2,26) 3 (0-8)** n.r 2,5 (1-6)** 1 (20)**** 
Relapsing patients, n (%) 5 (24) 5 (41.7) 10 (31) 8 (19.5) 30 (71.4) n.r 
Relapse rate, mean (SD) 0.4 (0-2)* 0.4 (0.2) n.r n.r n.r 1.1 (0.5-2.2) 
Time to second attack months (range) n.r n.r n.r n.r 11.5 (2-72) 3 (3-9)** 
Follow-up, months mean (SD) 38 (12-199)* 4.9 (2.9)*** 25.0  (1.9-169)** n.r 5.4 (2.6)*** 30 (11-152)** 
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n, number; SD, standard deviation; n.r, not registered; EDSS, Expanded Disability Status Scale; n.r, not reported. 
*mean (range), ** median (range), *** years mean (SD), **** EDSS>6, n (%) 
 
2.2 Laboratory features of AQP4-ab seropositive and seronegative LETM studies 
2.2.1 AQP4-ab seropositive LETM patients   
 
 
 
 
 Iorio R, et al.122 
Chang K-H, 
 et al.123 
Kitley J, et al.125 
Sung-Min K,  
et al.128 
Hyun JW,  
et al.124 
Jiao Y,  
et al.126 
Number of patients 16 18 44 9 55 42 
CSF Findings, n (%)       
          OCB 3/16 (19) 0 3/19 (16) n.r 3/43 (7) 5 (11.9) 
Pleocitosis n.r 3/25 (12)* 3/19 (16)* 7.13 (8,5)** 16/41 (39) 12 (28.6) 
          IgGIndex n.r 8 (32) n.r 0.6 (0.2)** 4/32 (12.5) 4 (9.5) 
         ANAs n.r 6/15 (40) nr 2 (2.2) 11/50(22) n.r 
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2.2.2 AQP4-ab seronegative LETM patients  
 
 
 
 
 
CSF, cerebrospinal fluid; OCB, oligoclonal bands; ANAs, anti-nuclear antibodies; n.r, not reported 
*pleocytoisis defined as >50 cells/ml     ** Quantitative results, n (SD) 
 
 Iorio R, et al.122 Chang K-H,  et al.123 Kitley J, et al.125 Sung-Min K,  et al.128 Hyun JW, et al.124 Jiao Y, et al.126 
Number of patients 21 12 32 41 42 5 
CSF Findings, n (%)       
        OCB 5/21 (24) 1/12 (8.3) 0 n.r 4/30(13.3) 0(0) 
       Pleocitosis n.r 0/13 (0)* 11/25 (44)* 8.6 (11.5)** 6/36(16.7) 2 (20) 
       IgG Index n.r 0 (0) n.r 0.6 (0.2)** 4/30(13.3) n.r 
      ANAs n.r 2/8 (25) n.r 4 (11.8) 0(0) n.r 
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2.3  Radiological features of AQP4-ab seropositive and seronegative LETM studies 
2. 3.1 AQP4-ab seropositive LETM patients  
 Iorio R, et al.122 Chang K-H, et al.123 Kitley J, et al.125 Sung-Min K,  et al.128 Hyun JW,  et al.124 Jiao Y, et al.126 
Number of patients 16 18 44 9 55 42 
MRI findings    n.r   
Patients with brain Lesions, n 
(%) 
8 (50) 9 (50) 32 (72.7)  55/55 (100) 32 (76.2) 
Length spinal cord lesions, 
mean (SD) 
5.5 (3) 5.6 (3) 7.5 (n.r)  7.4 (4.5) n.r 
Brainstem involvement, n (%) 10 (63.3) n.r n.r  n.r n.r 
Spinal cord involvement, n SD)            n.r 
Cervical 15 (94.4) 91 (67) n.r  13 (23.6) n.r 
Thoracic 8 (50) 42 (87.5) n.r  19 (34.6) n.r 
Cervico-thoracic 9 (56) n.r n.r  23 (41,82) n.r 
Conus n.r n.r 2 (6)  0 (0) n.r 
Central grey matter 
involvement, n (%) 
15 (94) 28 (58.3) n.r  41/44 (93.2) n.r 
Hypointense T-1 lesion, n (%) 12 (75) n.r n.r  40/44 (90.9) n.r 
Gad, n (%) 15 (94) n.r n.r  21/31 (67.7) n.r 
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2.3.2 AQP4-ab seronegative LETM patients   
n, number; SD, standard deviation; Gad, gadolinium enhancement; n.r, not reported.  
 Iorio R, et al.122 Chang K-H, et al.123 Kitley J, et al.125 Sung-Min K,  et al.128 Hyun JW,  et al.124 Jiao Y,  et al.126 
Number of patients 21 12 32 41 42 5 
MRI findings    n.r   
Patients with brain Lesions, n (%) 7 (33) 1 (8.3) 3 (9.3)  37/42 (88.1) 3 (60) 
Length spinal cord lesions, mean (SD) 4.6 (2.2) 4.9 (3.1) 7.6 (n.r)  4  (1.6) n.r 
Brainstem involvement, n (%) 0 (0) n.r n.r  n.r n.r 
Spinal cord involvement, n (SD)                                          n.r 
Cervical 13 (62) 16 (59.3) n.r  16 (38.1) n.r 
Thoracic 13 (62) 15 (55.6) n.r  19 (45.2) n.r 
Cervico-thoracic 5 (24) n.r n.r  4 (9.5) n.r 
Conus n.r n.r 10 (34)  3 (7.1)** n.r 
Central grey matter involvement, n 
(%) 
12 (57) 6 (22.2) n.r  32/33 (97) n.r 
Hypointense T-1 lesion, n (%) 7 (33) n.r n.r  20/32 (62.5) n.r 
Gad, n (%) 15 (71) n.r n.r  20/26 (76.9) n.r 
